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SUMMARY
The binding of carbenoxolone to crystalline bovine 
and human albumin was measured in vitvo by equilibrium 
dialysis, ultrafiltration and fluorescent probe techniques. 
Comparison of the results of these methods did not provide 
a good correlation, although it was clear that marked 
species differences in binding were evident with each 
method. Carbenoxolone and phenylbutazone share a single 
class binding site on bovine albumin, but are bound at 
different sites on human albumin.
A fluorescent probe technique was chosen to compare 
the binding of carbenoxolone with that of other drugs.
The binding of the probe, l-anilino-8-naphthaiene sulphorrie 
acid, to human albumin revealed two distinct binding sites 
on human albumin, which enabled the drugs to be classified 
into three groups. Two of the groups bind at only one 
site whilst the third group was bound at both sites.
Carbenoxolone was the most strongly bound member'of 
its group which included: cicioxolone, indomethacin, 
enoxolone and cholesterol. The second group of drugs 
comprised: flufenamic acid, phenylbutazone, warfarin, 
tolbutamide and imipramine. The remaining drugs, bound 
at both, sites, consisted of prednisolone, aspirin, : 
lbuprofen, chlorpropamide and phenytoin. It was inferred 
that carbenoxolone would displace the other members of 
its group, would not displace the drugs in group 2, and 
may displace the drugs in group 3 from their common 
binding sites.
Models of interaction in vivo were established using 
the rat, whereby phenylbutazone was shown to potentiate 
the pharmacological activity of warfarin, tolbutamide 
and chlorpropamide. In the same models carbenoxolone 
was without effect on these drugs. Neither phenylbutazone
nor carbenoxolone affected the activity of phenytoin in 
the rat', probably due to the relatively low protein binding 
of phenytoin in the rat.
Further studies in the rat demonstrated a decrease 
in the plasma half-life of warfarin and an increase in 
the whole blood half-life of tolbutamide when phenylbutazone 
was co~admini.stered. Carbenoxolone did not alter the 
pharmacokinetics of these two drugs.
Serum concentrations of carbenoxolone in both rat 
and man were unaltered by the concomitant administration 
of warfarin, tolbutamide, chlorpropamide or phenytoin,
In conclusion, carbenoxolone was shown to be free 
from many of the displacement interactions demonstrated 
with"other drugs which are bound to plasma proteins.
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INTRODUCTION.
It has long been recognised that the binding-of 
various drugs to plasma proteins may influence profoundly 
the free concentration of such agents and thus markedly 
alter the magnitude and duration of the pharmacological 
response. Carbenoxolone sodium is a potent ulcer-healing 
drug which is extensively bound to plasma proteins and 
has, as yet, received little study for possible drug 
interactions. This introduction attempts to give the 
general background of drug interaction, protein binding 
and the drug carbenoxolone.
1.1 DRUG INTERACTION
A drug interaction is said to have occurred when the 
presence of one drug modifies the pharmacological activity 
of another (Stockley, 1971). In this context the ’second 
drug’ may include food, food additives, pesticides, 
industrial chemicals, or any ’xenobiotics’ (Parke, 1972a; 
Sapeika, 1976).
Modern drugs -perse are usually selectively-toxic 
chemicals which exert their mode of action by a variety 
ox specific actions. For example, selective toxicity to 
an organism, in the case of antibiotics, to malignant cells 
with cytotoxic agents, or by influencing normal physio­
logical function as with hypoglycaemic agents, anti­
coagulants, oral contraceptives, diuretics and 0 -adrenergic 
blockers. When the site of action of these drugs is 
limited to its pre-designated site, side-effects, or 
toxicity per se may be low. However, if the drug enters 
into an interaction with another drug, or chemical, one 
of a number of consequences may ensue which are briefly 
summarised in Table 1.1.
Introduction of the practice of ’polypharmacy' has 
resulted in an increased risk of drug interaction. From
Table 1.1 SUMMARY OF POSSIBLE CONSEQUENCES OF 
DRUG--XENOBIOTIC INTERACTIONS
Mode of interaction Possible consequences
Chemical Failure of drug absorption 
e.g. di- and tri-va.lent metal' 
salts with tetracyclines
Prevention of 
absorption
Failure to reach site of 
action e.g. cholestyramine 
with acidic drugs
Increase in drug 
metabolising enzyme 
activity
Increased drug metabolism 
e.g. phenobarbitone with 
phenytoin
Prevention of 
metabolism and/or 
excretion
Potentiation, by failure to 
remove drug from site of 
action e.g. probenecid with 
penicillin
Displacement from 
plasma binding sites
Potentiation, by increase of 
drug concentration at its 
site of action e.g. phenyl­
butazone with warfarin
a recent survey (Editorial, 1973), it is evident that one 
in five British women of child-bearing age is taking an 
oral contraceptive agent, and one in six of the adult 
population is taking a psychotropic drug. From these two 
classes of drug alone it is shown that about one in sixty 
of the population .is regularly taking two drugs. Even 
this rate of interaction does not include over-the-counter 
medications, methylxanthines in beverages, alcohol intake, 
cigarette smoking or environmental xoollutants.
Thus studies of drug interactions are useful in that 
they may lead to the ability to predict and avoid them 
before they occur clinically in man.
The key factor in drug interactions may be seen, 
from the earlier definition, to -be bioavailabilityf The 
bioavailability of a drug can be altered in many ways.
Let us first consider the. types and consequences of. drug. . 
interactions:
1.1.1 CHEMICAL INTERACTIONS
This is essentially a pharmaceutical problem and has 
been considered under the guise of .compatabilities.
The problem of compatability arises less in present 
times than formerly, due to compound prescription 'powders’ 
’mixtures' and 'pills’, being replaced by the unit dosage 
’capsule’, ’tablet’ or ’proprietary mixture'. However, 
in the practice of ward pharmacy it is very relevant.
The addition of drugs to -intravenous fluids is considered 
a safe and convenient route of administration, especially 
in unconscious patients or those who are susceptible to 
vomit an orally administered drug. In a recent survey of 
ten hospitals, 39% of intravenous administrations over a 
period of one month (7,900 infusions) had had at least 
one drug included in the intravenous infusion (D’Arcy & 
Thompson. 1974). Interactions which occur tend to be the
result of an incompatible physico-chemical environment 
for the. added drug.. 'Salting out’ of .sparingly. soluble.. ... 
antibiotics such as ampicillin can readily occur with the 
addition of other drugs or electrolytes. The mixing of 
drug solutions in the syringe is also subject to similar 
restrictions of changes in pH or in complex formation.
Such an example is the mixing of soluble insulin and 
protamine zinc insulin whereby excess zinc ions combine 
with the soluble insulin to form the delayed complex and 
thus result in inadequate immediate glucose-lowering 
activity (Alstead/dt al3 1971; Goodman & Gilman, 1975b).
The co-administration of di- and tri-valent metal 
ions such as aluminium, calcium, magnesium and iron, with 
tetracyclines greatly reduces serum levels of the anti™ ; 
biotic (Levy, 1970; Neuvon en e t .  al3 1870). The. efficacy- 
of early formulations of tetracyclines was reduced by 
the use of calcium phosphate, a common ’filler’ of 
capsules.
1.1. 2 DRUG ABSORPTION INTERACTIONS ; (-4
Many factors may influence the absorption of drugs - 
from the gastro-intestinal tract, a primary influence 1 
being tablet disintegration.
A reduction of gastric pH favours absorption of 
acidic drugs such as salicylates, phenylbutazone, warfarin 
and phenytoin by promoting the unionised lipid-soluble 
forms of the drug'. Conversely the co-administration of . 
antacids will reduce the absorption of such drugs 
as tetracyclines (Barr, et als 1970).
Anticholinergics and opiates delay gastric emptying 
and majT- thus delay or reduce the absorption of other drugs. 
A reduced peristaltic activity may also retard tablet 
dissolution rates. Nimmo and colleagues- (1973) have shown 
that propantheline bromide delayed gastric emptying and
slowed the absorption of paracetamol. Again the converse 
situation is to be considered. An increased absorption. 
of alcohol and paracetamol is seen with such drugs as 
metacloprarnide which increase gastric emptying rates 
(Stockley, 1974).
Ionic complexes may be formed in the intestinal 
tract which prevent drug absorption,.such as with calcium, 
and tetracyclines (section 1.1.1). Cholestyramine is an 
ion-exchange resin with an affinity for acidic molecules 
and is used to increase the excretion of bile salts by 
ion-exchange in such conditions as pruritis of partial 
biliary obstruction. The consequent prevention of fat 
and cholesterol absorption may lead to steatorrhoea and 
inhibition of absorption of the lipophilic vitamins: A,.. D . 
-and K. The malabsorption of vitamin K is of importance 
.in anticoagulant therapy with warfarin (see later this 
section). Cholestyramine can also form complexes with 
acidic drugs such as aspirin, phenylbutazone and warfarin, 
thus interfering with their intestinal absorption (Gallo, 
et a b . 1965; Koch-V/eser & Sellers, 1971) .
One drug may directly affect the absorption' of another 
and it is well known that barbiturates may inhibit the 
absorption of coumarin anticoagulants (Stockley, 1974). 
Whilst it is believed that induction of drug-metabolising 
enzymes by barbiturates (section 1.1.3) may be a factor in 
the reduced anticoagulant activity of the coumarins during 
co-administration-of barbiturates, Aggeler and O'Reilly 
(196 8) have shown that heptabarbitone will delay the 
absorption of bishydroxycoumarin. Similarly phenobarbitone 
will delay absorption of griseofulvin (Riegeleman, et al3
1970) and p-aminosalicylic acid will delay rifampicin 
absorption (Boman,ei al3 1970). The latter interaction was 
of particular interest because of the nature of combined 
therapy in tuberculosis treatment.However, it is now 
known (Griffin & D'Arcy, 1975a) that it was not p-amino-
salicylic acid itself but bentonite in the granulation 
which was preventing absorption. This is of even greater 
significance in that bentonite is a constituent of many 
proprietary and ethical mixtures.
Increased lipid absorption, from a high dietary fat 
intake, leads to the more ready absorption of lipophilic 
drugs such as griseofulvin and the anthelmintic, 
trichlorethylene. The increased absorption may be 
beneficial in the case of griseofulvin but not with 
trichlorethylene (Crounse, 1961). Decreased intestinal 
absorption is often an advantage with such preparations 
as the anthelmintics bephenium hydroxynaphthoate and 
trichlorethylene which show increased efficacy and 
decreased toxicity if they are not absorbed.
Antibiotic therapy suppresses the production of 
vitamin K by intestinal microflora and is thus often 
considered to potentiate anticoagulant therapy. Neomycin 
is known to potentiate warfarin (Udall, 1965; 1970) but 
it is understood that both a reduction of intestinal 
bacteria and a reduced dietary intake of vitamin K are 
necessary to produce symptoms of vitamin K deficiency in 
man (Editorial, 1968). However, it is known that neomycin . 
can induce steatorrhoea (Falcon, et al3 1966) and it is 
by this means that neomycin is likely to cause malabsorption 
of vitamin K, from whatever source. Other antibiotics 
may only reduce bacterial vitamin K production.
1.1. Z INTERACTIONS INVOLVING THE DRUG-METABOLISING ENZYMES
Induction of the drug-metabolising enzymes, which 
can lead to tolerance by a more rapid deactivation of the 
drug, is well known with such drugs as barbiturates, 
imiprarnine and phenylbutazone. When one drug induces 
drug-metabolising enzymes which also affect the metabolism 
of a second drug, then this constitutes an indirect 
interaction.
About 200 drugs are known to induce the microsomal 
hydroxylating enzymes of the liver, including the cytochrome 
P450 system (Griffin & D ’Arcy, "1975b). The ability of 
cytochrome P450 to catalyse other metabolic processes 
including deaikylation, oxidative deamination and 
sulphoxidation leads to the ability of one drug to 
stimulate the metabolism of other drugs which are not 
structurally related (Pearson & Havard, 1974).
Cigarette smokers also have an increased enzymic 
ability to metabolise 3,4-benzpyrene or related polycyclic 
hydrocarbons and show an increased metabolism of nicotine 
(Conney, et al3 1957; Beckett & Triggs, 1967). Kerri-Szanto 
and Pomeroy (1971) not only demonstrated an increased 
metabolism of the analgesic pentazocine in smokers 
compared with non-smokers, but also in urban compared to 
rural dwellers. Other environmental xenobiotics, 
including chlorinated hydrocarbon pesticides, are also 
known to stimulate the drug-metabolising enzymes (Hart, 
et als 1963). Barbiturates as a class are well known to 
induce liver microsomal enzymes and the combination of 
phenobarbitone with phenytoin in epileptic patients is a 
well-established therapy. Phenobarbitone will lower 
plasma levels of phenytoin and induce the more rapid 
excretion of the latter (Reynolds, 1967). The resulting 
lowered anticonvulsant activity of phenytoin is not 
clinically significant in that phenobarbitone itself 
possesses similar anticonvulsant activity. However, if 
the phenobarbitone is withdrawn, plasma levels of phenytoin 
increase and may lead to phenytoin toxicity. Similarly, 
barbiturates decrease the activity of warfarin (Levy,et ats
1970), griseofulvin (Riegeleman, et ai9 1970) and oestrogens 
(Conney, 1967).
Conversely, drugs which inhibit liver microsomal 
enzymes are likely to potentiate "the activities of other 
drugs, such as chloramphenicol, with oral hypoglycaemics
(Christensen & Skovsted, 1969) and monoamine oxidase 
inhibitors (MAOI) with barbiturates (Domino, et al3 1962). 
Most drugs which induce liver microsomal enzymes will 
initially demonstrate an inhibition prior to induction.
In the case of MAOIs, potentiation of natural amines 
present in foods, such as cheese, yeast extracts and 
pickled herrings, may occur leading to hypertensive crises 
(Blackwell, 1963; Nuessle, et al3 1965; Blackwell & Marley, 
1966; Cooper, 1967). It is thought probable that the 
mode of action of chloramphenicol in potentiating the 
anticoagulant activity of coumarol is by depression of 
coumarol biodegradation in the liver causing a 3- to 4- 
fold increase in both the plasma half-life and the activity 
of the anticoagulant (Christensen & Skovsted, 1969). 
Similarly, tolbutamide and phenytoin are potentiated by 
chloramphenicol.
1.1.4 DRUG INTERACTIONS INVOLVING EXCRETORY MECHANISMS
The principal routes of excretion of drugs and their 
metabolites are via the urine and bile (Parke, 1968a). 
Agents such as general anaesthetics may reduce renal 
blood flow and thus decrease the glomerular filtration 
rate, reducing drug excretion in general. Diuretics may, 
by increasing urine flow, cause an increased urinary 
excretion of drugs. For example, indomethacin efficacy 
is reduced by concomitant administration of frusemide 
(Brooks, et al3 1974a).. Most drugs which are not protein- 
bound pass into the renal tubule lumen and are reabsorbed 
by simple diffusion or active transport.
As most drugs are weak electrolytes, only the 
unionised forms, being lipid soluble, are accessible to 
passive reabsorption. Weak bases such as amphetamine, 
imipramine and pethidine, are less easily reabsorbed 
from urine at a low pH and are thus excreted more readily. 
At a urine pH of 5.0, 50% of a dose of amphetamine is 
excreted by man within 16 hours, whereas at pH 8.0 oniy
3% is excreted in the same time (Beckett, et al3 1965).
Many acidic drugs are actively secreted in the proximal 
tubules. Thus competition between drugs for this active 
transport mechanism may lead to a prolonged plasma life 
of the displaced drug. Phenylbutazone will prevent the 
renal excretion of hydroxyhexamide, an active metabolite 
of acetohexamide, leading to an enhanced hypoglycaemic 
activity (Field, et al3 1967).
Probenecid is used to reduce the renal tubular 
secretion of penicillin by competing for the active 
transport mechanism, probenecid itself being actively 
reabsorbed at a later stage to continue its potentiation 
of the antibiotic. This interaction with probenecid is 
particularly useful in the treatment of cases of 
cholecystitis, whereby the biliary excretion of penicillin 
and of the semisynthetic penicillins is increased 
(Sales, et al3 1972). Similarly, probenecid potentiates 
indomethacin activity by reducing its excretion (Brooks, 
et als 1974b). Probenecid is also used as a uricosuric 
agent, exerting its activity by competing with uric acid 
for active reabsorption.
The extent of biliary excretion of a xenobiotic is 
influenced by physico-chemical factors including molecular 
weight (Smith, 1973). Biliary-excreted drugs are 
concentrated in the bile by active transport (Parke, 1968a) 
and, presumably, simultaneously-administered drugs may 
compete for this active process.
1.1.5 PHYSIOLOGICAL INTERACTIONS
Interaction between competitive blocking agents and 
endogenous substances, such as atropine and acetylcholine, 
mepyramine and histamine, bromolysergic acid and 5- 
hydroxytryptamine, are well known but are rarely 
considered with drug interactions because the consequences 
of such interactions are the object of the use of the _
drugs. However, where the mode of action of one or more 
drugs lies in the alteration of a physiological mechanism, 
then the results of concomitant use may result in 
interaction. Drugs which act on the adrenergic neurone 
illustrate this principle well.
The guanide adrenergic blocking agents, such as 
guanethidine and bretylium, exert their activity by 
preventing the release of noradrenaline from the 
adrenergic neurones. In order to exert this influence 
they must be taken up into the neurone by the active 
mechanism which takes up noradrenaline back into the 
neurone. Tricyclic antidepressant agents, such as 
imipramine and amitriptyline, are potent competitive 
inhibitors of the noradrenaline uptake mechanism so that 
these drugs will depress the hypotensive actions of the 
guanides (Leishman, et al3 1963). There is some evidence 
that the guanides, in reducing noradrenaline release, 
render the adrenergic receptor more sensitive to 
stimulation. Thus, if directly-acting sympathomimetic 
drugs are given to guanide-treated patients they may 
cause an increased adrenergic reaction which is prolonged 
due to competition for noradrenaline uptake between the 
guanides and the sympathomimetics (Boura & Green, 1962). 
Similarly, indirectly acting sympathomimetics antagonise 
the hypotensive activities of the guanides (Boura & Green, 
1962; Sneddon & Turner, 1969). In reserpinised patients 
or animals, where the noradrenaline stores are depleted, 
directly-acting sympathomimetic agents have enhanced 
activity due to increased receptor sensitivity. Conversely, 
indirectly acting sympathomimetics, which rely on inducing 
noradrenaline release, are reduced in activity (Moore & 
Moran, 1962).
1.1.6 • INTERACTIONS AT PLASMA BINDING SITES
After absorption many drugs enter the blood and bind 
to plasma proteins, usually albumin, and their tissue
distribution is often a function of their protein binding 
affinity. This binding to plasma proteins is reversible 
and in a constant state of equilibrium. It is the free 
or unbound portion that is generally considered to be the 
bioactive component of the drug (Rolinson, 1964). Where 
two drugs share a common binding site they will compete 
with each other for that site. A drug with a high 
affinity for a binding site will quantitatively displace 
a drug with a lower affinity, resulting in an increased 
level of free displaced drug. If the displaced drug is 
only bound to a small extent, say 50%, then a displacement 
of 5% is of little pharmacological consequence; whereas 
if a drug which is extensively bound, say 98%, is 
displaced so that only 96% is bound, this represents a 
two-fold increase in the free concentration of the drug 
and potentiation of its activity (Prescott, 1969). This 
type of interaction is demonstrated between warfarin and 
phenylbutazone.
Both warfarin and phenylbutazone are highly bound 
to plasma proteins at around 99% and 98% respectively, 
but phenylbutazone has the greater binding affinity a n d . 
will displace warfarin, potentiating its anticoagulant 
effect by increasing the free concentration of the drug 
in the liver (Aggeler, et al3 1967; Udall, 1970; O'Reilly 
& Levy, 1970). It is interesting to note that the plasma 
half-life of warfarin is reduced as a consequence of more 
drug being available for hydroxylation in>the liver, thus 
the potency is enhanced but not the duration of action. 
There has been a suggestion that enzyme induction by 
phenylbutazone is responsible for the decreased plasma 
concentration of warfarin, but this has only been 
demonstrated in animals and occurs only after the first 
few days of treatment (Welch, et ai3 1969). .
Similar displacement .interactions have been reported 
from studies in vitro between phenylbutazone, warfarin,
indomethacin and tolbutamide, the. binding affinities 
decreasing in the order given, thus each drug may be 
displaced by those preceding it (Assandri & Perazzi,
1976). Displacement interactions in vivo are seen between 
warfarin and mefenamic acid (Sellers & Koch-Weser, 1970;
1971), sulphonamides and sulphonylureas, phenylbutazone 
and sulphoxidine (Wardell, 1971).
A delayed interaction is precipitated after with­
drawal of chloral hydrate from warfarin-treated patients. 
Chloral hydrate is metabolised to trichloracetic acid, 
which is strongly bound to plasma proteins and will 
displace warfarin from plasma binding sites. However, 
the anticoagulant effect of warfarin is not. increased 
because chloral hydrate also induces a hydroxylating 
enzyme resulting in lower plasma warfarin concentrations. 
Thus whilst both drugs are given there is no 
pharmacological change but withdrawal of the hypnotic 
and maintenance of the same dose of anticoagulant has 
produced fatal haemorrhage (Cucinell, et dl3 1966).
1.2 PROTEIN BINDING
Interaction of small organic ions with proteins has 
been the subject of multidisciplinary research for many 
years (Goldstein, 1949). Early investigations dealt 
largely with the qualitative aspects of organic binding 
on both acidic and basic sides of the protein iso-electric 
point. The organic anions investigated were often dyes, 
probably due to the relatively limited technology 
available to assay the anions themselves. However, 
quantification and interpretation of binding data 
incorporating the law of Mass Action was introduced in 
studies on bovine serum albumin fractions by Klotz and. 
co-workers (1946; 1948) and Scatchard (1949). The field 
of study was expanding by this time and has been the 
subject of several comprehensive reviews commencing with 
the classical review of Goldenstein (1949),' and followed.
by Meyer and Guttman (1968), Jusko and Gretch (1976) and 
Vallner. (1977).
1.2.1 DESCRIPTION AND DEFINITION
Protein binding is a reversible interaction between 
a small molecule and a protein. This binding is analogous 
to -the enzyme-substrate interaction except that it does 
not result in degradation or formation of new products; 
it is also analogous to most drug-receptor complexes 
where covalent binding does not occur. This interacting 
small ion is sometimes referred to as a ligand.
The ionic interaction forces involve hydrogen 
bonding, hydrophobic bonding, electrostatic forces and 
van der Waal forces. The relative importance of these 
influences has been compared by Davison (1971), who 
reviewed various measurements on related structures 
(see Table 1.2). The exact contribution or importance 
of each type of inter-molecular force in protein-ligand 
binding is unknown but it has been debated that hydrogen 
bonding is not dominant whilst hydrophobic interactions 
are important (Klotz, 1973).
These suggestions were based on the positive 
entropies associated with hydrophobic ligands but were 
also found to be present with non-polar ligands where 
only electrostatic forces were involved (Klotz & Fiess,
1951; Kauzmann, 1959). Changes in enthalpy have been 
taken as indicators of van der Waal involvement in binding 
(Steinhardt & Reynolds, 1969). Hansch and co-workers 
(1965) derived a model of binding which was mechanistically 
similar to phenol partition between water and octanol 
and concluded that binding was non-specific and due to 
hydrophobic bonding.
However, only where studies using X-ray crystallography 
have been used can an evaluation of precise binding
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locations be made. Such a study is that of Arnone (1972), 
on diphosphoglycerate binding to haemoglobin, where it 
was found that electrostatic forces were responsible for 
this binding.
As the binding, of ligands is reversible, the complexes 
will obey the law of Mass Action and will be in a state 
of equilibrium.
CPU + CD3 ^  CPDD
where CPU = free protein concentration
CDD = free drug concentration
CPDD = drug-protein concentration
Thus at equilibrium an apparent association constant
(K ) may be formulated: a
(K ) = — ETO3-
a CPU CDD
Thus it is clear that the proportion of a bound 
ligand will be related to the apparent affinity constant 
K and the number of binding sites per molecule.cl
1.2.2 FUNCTION OF PROTEIN BINDING
That protein binding exists as a specific function 
is highly probable because specific binding proteins have 
been discovered, in plasma, to bind hormones like 
testosterone and thyroxine and substances such as vitamins 
A and B ^  anc* corticosteroids. The binding is likely to 
be a means of transportation in an inactive form and has 
been described at length (Desgrez & De Traverse, 1966; 
Steinhardt & Reynolds, 1969).
Of the blood 'proteins albumin is by far the most 
common substrate for binding of all classes of ligand. 
Albumin may have a low affinity for the specific ligands 
mentioned above.but a high binding capacity*, whereas the
specific binding proteins, such as corticosteroid-binding 
globulin, bind steroids like prednisolone'with a high 
affinity but low capacity. When the binding sites on 
corticosteroid-binding globulin are fully occupied the 
steroids bind to albumin with a low affinity but a high 
capacity. In consequence, at low albumin levels 
(2.5g/dl), side-effects due to free prednisolone appear 
(Lewis, et al3 1971). Fatty acids and prostaglandins are 
known to bind well to albumin, which may prove to be the 
transport protein for these endogenous substances (Brodie, 
1966; Gugler, et al3 1974; Gueriguian, 1976). It is also 
probable that protein binding plays a role in the dietary 
absorption and transport of such hydrophobic molecules as 
fatty acids. Most drug-protein binding studies investigate 
this binding and transport function which is usurped by 
the ’xenobiotics’ and may affect the drug activity in some 
of the ways mentioned in the following section.
1.2.3 PROTEIN BINDING INFLUENCES 
Drug absorption and distribution
It is widely accepted that, because macromolecules 
and macromolecular complexes pass across membranes only 
with difficulty, plasma protein binding can influence the 
distribution pattern of drugs. A drug of low aqueous 
solubility will have a higher plasma concentration if it 
binds to plasma proteins, thus increasing .its apparent 
solubility gradient between the gut and blood (Goldstein, 
1949; Brodie, 1966). This raised plasma concentration 
will thus increase the drug’s availability to other 
tissues and hence its efficacy.
Martin (1965) produced a theoretical model of drug 
binding and correlated drug availability with various 
binding affinities. He stated that a drug is distributed 
within two aqueous compartments, plasma and tissue fluid, 
and that it is in a state of equilibrium between the two.
Thus a highly bound drug at low dose levels will be 
concentrated in the plasma compartment, whilst at the 
threshold of saturation a small increase in the dose 
level will greatly increase the concentration of available 
drug. Similarly a less strongly bound drug will achieve 
a higher tissue concentration. Martin concluded that a 
Change in the protein binding will significantly alter 
the distribution of highly bound drugs only where the 
free concentration is small.
Metabolism and excretion
Where a drug is strongly bound to plasma proteins, 
the concentration in the liver may well be much less than 
the plasma concentration and, in consequence, the rate 
of metabolism may be slow. Levy and co-workers have 
demonstrated this effect with the coumarin anticoagulants. 
The ratio between liver and plasma, drug concentrations 
reflects the degree of plasma binding and, for bishydroxy- 
coumarin, is higher in the rat than in man (Nagashima, 
et at> 1968). In consequence the plasma half-life of 
bishydroxycoumarin is less in the rat than in man. The 
free fraction of warfarin in plasma is variable between 
Individuals and is not related to total plasma concentration 
however, the clearance rate is directly, proportional to 
the free concentration of the drug (Levy & Yacobi, 1974). 
Furthermore, the pharmacological potency of warfarin was 
directly correlated with its biological half-life (Yacobi, 
et at,y 1974). Similar results were obtained for dicoumarol 
(Jahnchen & Levy, 1974).
These results from animal studies have been confirmed 
clinically where a hypoalbuminaemic patient (1.6g/dl) 
proved to be resistant to the pharmacological action of 
warfarin and the plasma half-life of the drug was six 
hours in comparison with the normal two days (Lewis, et al3 
1967). In a study of cardiovascular patients, who had 
been individually established on warfarin1 therapy, the.
variation of free warfarin concentration was less than 
the variation of total warfarin concentration. However, 
no correlation was seen between prothrombin times and 
the free concentration of warfarin, . indicating that, in 
man, variables other tharj protein binding were affecting 
the anticoagulant action (Yacobi, et al3 1976a). The 
intrasubject levels in these patients were unaltered 
after three to six months’ therapy, indicating that inter­
subject variations were not due to enzyme induction 
(Yacobi, et al3 1976b).
Thus these findings with warfarin clearly demonstrate 
that its metabolism and pharmacological consequences are 
governed, in part, by the degree to which the drug is 
bound to plasma, proteins.
Similarly, studies with propanolol have shown that 
its plasma half-life is directly proportional to its 
degree of plasma binding in animals and in man (Evans, 
et al9 1973; Evans & Shand, 1973). Further studies have 
shown the protein binding of phenytoin (Lund, et al3 1972), 
sulphonamides (Seydel, 1970) and naproxen (Runkel, et al3 
1974) to influence the plasma half-life and/or clearance 
of each drug. It has also been suggested (Glassman, et 
at3 1973) that variations in the binding of imipramine, 
between 5 and 23%, may account for the inability to 
correlate plasma levels, plasma clearance and clinical 
response. However, with such a weakly bo’und drug it is 
possible that other factors are responsible.
The association-dissociation rates between albumin 
and ligands are so rapid that they probably do not 
directly affect the rate of metabolism of the ligand 
(Meyer Si Guttman, 1968). For example, phenylbutazone is 
highly bound to p-lasma proteins in several animal species 
including man; whilst, in most species except man, it is 
rapidly excreted (Brodie, 1962).
Protein binding in diseased3 neonatal and elderly patients
Albumin is the principal binding protein in plasma 
and its concentration in plasma may be lowered from normal 
in certain clinical conditions such as renal dysfunction, 
burns, post-surgery, bronchitis and other chronic diseases. 
Plasma albumin concentration may also be considered 
’abnormally low’ in neonatal and elderly subjects 
(Reidenberg, 1974; Jusko & Gretch, 1976; Vallner, 1977).
If albumin concentrations are lowered then the capacity 
for drug binding is lowered, either leading to an 
increased concentration of free drug at normal dosage, or 
to an increased danger of displacement interaction. The 
rapid elimination of warfarin in a hypoalbuminaemic patient 
was mentioned previously (Lewis, et al3 1967).
Disease. The ratio between extravascular and intra- 
vascular albumin (normally 1.2 to 1.8) is altered in many 
diseased states, and in particular by prolonged bed rest. 
Five paraplegic patients confined to bed, post-operatively, 
for two months had an extravascular/intravascular albumin 
ratio (EV/IV) more than twice normal (PI ant in, etaZ-., 1971). 
Various surgical procedures, especially abdominal surgery, 
are known to reduce plasma albumin levels by as much as 
0.5g/dl (Mourisden, 1967). Burn injury understandably 
gives rise to albumin loss, because the largest extra­
vascular compartment of albumin is contained in the skin 
(Birke, et al3 1968). Albumin concentrations fall directly 
with the progress of neoplastic diseases with an average 
fall in one study of l.Og/dl (Midler., et al3 1950;
Steinfeld, 1960).
Patients with renal dysfunction may have a lowered 
albumin concentration but often have a raised plasma urea 
concentration which can reduce the binding capacity of 
the albumin, especially for. acidic drugs. A reduced 
plasma binding of phenytoin in hyperuraemic patients was 
observed which was not directly dependent on albumin or
total protein concentrations, or related to the presence 
of dialysable products in the plasma (Reidenberg, et al3
1971). These results were confirmed by Blum and 
colleagues (1972) who also demonstrated that the principal 
metabolite of phenytoin was not responsible for a 
competitive inhibition. Andreasen (1973) has also 
observed a reduced binding of phenytoin in hyperuraemic 
patients but was later able to demonstrate an increased 
binding of phenytoin in vitro in dialysed plasma from both 
normal and hyperuraemic patients (Andreasen, 1974). These 
findings suggested either (a) the presence of a non- 
dialysable competitor; (b) the presence of a very highly 
bound ligand; or (c) a physical alteration in the 
albumin quaternary structure. The latter is also 
suggested by Shoeman and colleagues (1973). Both normal 
and hyperuraemic patients stabilised on phenytoin therapy 
have a similar plasma concentration of free drug 
(Odar-Cederlof ■& Borga, 1974), whilst a subsequent study 
has shown that the distribution of phenytoin between 
plasma and erythrocytes is altered in hyperuraemic 
patients (Ehrnebo & Odar-Cederlof, 1975).
As the liver is the site of synthesis of albumin, 
liver dysfunction may be expected to result in low 
plasma albumin concentrations, associated with a decreased 
total drug-binding capacity. Cirrhosis is a common, 
complex disorder often associated with a history of 
chronic alcoholism (Kradjan, 1973). ^Although plasma 
albumin concentration is low in cirrhotic patients, the 
total albumin mass is only slightly reduced, due to an 
expanded plasma volume, whilst the EV/IV ratio is also 
slightly lowered (Dykes, 1968). Further studies on 
alcoholic liver disease patients have shown that, as a 
group, they bind basic drugs less well than normal 
patients, free concentrations of quinidine being increased 
three-fold. However, the plasma protein binding of 
acidic drugs varied, without a direct correlation with 
liver disease (Reidenberg, 1974; Affrime & Reidenberg, 1975).
Viral hepatitis is also responsible for lower 
albumin synthesis and consequent reduction in circulating 
albumin (Jusko & Gretch, 1976). Phenytoin binding is 
reduced by up to 30% in viral hepatitis patients (Blaschke, 
et al3 1975).
• Age. Drug disposition in neonates is different to 
that in adults partly due to the greater body water 
content, and lower fat content, of neonates. Therefore, 
protein binding plays an important role in the regulation 
of.pharmacokinetics in neonates (Yaffe & Juchau, 1974).
Bound fractions of phenytoin and.salicylate are lower in 
neonates than in adults, The increased concentrations 
of the free drugs were paralleled by an increase in serum 
bilirubin concentration, suggesting a possible competitive 
displacement of the drugs from serum albumin by bilirubin 
(Krasner, et al3 1973). Nafcillin was very much less 
bound in the neonate, although a subsequent study 
revealed that albumin was not the primary binding site 
of this drug (Krasner & Yaffe, 1975),
Although neonatal plasma contains less albumin there 
is evidence to conclude that the reduced binding of drugs 
is due largely to competition from free fatty acids and 
bilirubin (Fredholm, et al3 1975). Two studies comparing 
the binding of phenytoin, imipramine, diazoxide and 
cephalothin in neonates and adults demonstrated a
a
correlation between the lower binding in the neonate with 
decreased plasma albumin concentration, and also revealed that 
neonatal hyperbilirubinaemia was a contributing factor 
(Pruit & Dayton, 1971; Ehrnebo, et al3 1971).
The elderly are known to have a lower plasma albumin 
concentration than younger .sub jects, possibly associated 
with a decreased mobility (Woodford-Williams, et al3 1965). 
This puts the elderly in the category of hypoalbuminaemic 
patients, mentioned earlier. Hayes and colleagues (1975a;
1975b) have demonstrated a decreased total binding 
capacity for warfarin and phenytoin in the blood plasma 
of the elderly. Changes in binding affinities were not 
altered in elderly patients and the decrease in clearance 
rate of phenytoin correlated with decreased albumin 
levels. Yacobi and.colleagues (1976a) in a study of 
mixed young and elderly patients showed a similar 
correlation of warfarin clearance with the plasma 
concentration of free drug. However, in a subsequent 
study in elderly patients, the clearance rate of carben- 
oxolone sodium was decreased even though the total binding 
capacity was also decreased because of lower albumin 
concentration (Hayes, et al3 1977). Thus there appears 
to be no structural impedance to the binding of drugs to 
albumin in the elderly, only a reduced total capacity for 
binding. This, together with a possible decreased hepatic 
clearance, may lead to higher plasma concentrations of 
drugs on repeated dosage and thus adverse reactions.
Species difference
Differences in protein binding of drugs such as;..warfarin 
between young and elderly patients and between.healthy ■ 
individuals have been mentioned. It is not surprising therefore that 
correlation between animal species and man. is often a non sequitur.
Phenytoin is bound more strongly to plasma proteins 
in man than in the rat, the difference being reflected in 
the longer plasma half-life in man (Conard, et al3 1971).
It is interesting to note that the principal metabolite 
of phenytoin, p-hydroxyphenytoin, is bound less strongly 
in man than in the rat, the free levels of the metabolite 
being associated with gingival hyperplasia.in man but not 
in the rat. Similarly the plasma half-lives of propanolol 
and diazepam, together with their, metabolites, have been 
correlated with the plasma binding affinities in several 
speciesi In the species where the degree of binding is 
high the plasma half-life is long, so that only for some
species may these drugs be considered to be highly bound 
(Evans, et al9 1973; Klotz, et al9 1976). Rieder (1963) has 
reported a correlation between.drug distribution and the 
unbound drug fraction for various sulphonamides in the 
rabbit. Ruiz-Torres and Meinig (1965) could find no such 
correlation in the rat.
Studies with bovine and human serum albumin in vitro 
have indicated that the presence of fatty acids minimised 
the observed differences in testosterone binding between 
the albumins of the two species (Ryan & Chopra, 1976).
The number of binding sites for testosterone varied between 
9 and 10 for untreated human albumin and between 5 and 6 
for de-fatted albumin. In contrast, for bovine albumin 
there was only 1 site.on the untreated material which 
became 5 for the de-fatted albumin. These results provide 
the unusual data that the presence of fatty acids increases 
the binding of testosterone in contrast to the frequently 
seen reductions in binding (Chen, 1967). Both imipramine 
and its metabolites are bound to bovine serum albumin to 
a greater extent than to human serum albumin (Weder &
Bickel, 1970). Low concentrations Of salicylate have a 
higher affinity for human serum albumin than for bovine 
serum albumin, leading to the suggestion that the difference 
in. binding involves e -amino and possibly guanido groups 
(Davidson & Smith, 1961). Using a gel filtration technique 
to measure salicylate binding to plasma proteins, Sturman 
and Smith (1967) were able to differentiate between 
various species where either a low- or high-order binding 
affinity for salicylate was observed. Baboon, rat, mouse, 
horse, dog, toad, rabbit and turkey formed a group with a 
low-order affinity for salicylate, and man, monkey (macaca 
mulata) and guinea pig, possessed a high-order affinity, 
suggesting that those in the low-order group are deficient 
in c-amino and guanido groups on their plasma albumins.
In contrast, Kucera and Bullock (1969) used equilibrium 
dialysis to measure the binding of salicylate to plasma
proteins and their results also enabled differentiation 
between' species with high- and low-order affinity for 
salicylate. Rat and dog possessed a low-order affinity, 
while man, green monkey, rabbit and guinea pig had a high- 
order affinity. It was suggested that the differences in 
the results w7ith rabbit albumin, between these authors 
and others (Sturman & Smith, 1967), were due to the 
different methodology, in that Sephadex Gel is known to 
bind acidic drugs such as salicylate.
In contrast, similar binding affinities for a range 
of prostaglandins have been observed for both human and 
bovine serum albumin (Gueriguian, 1976),.and for prosta­
glandin Eg with both rat and human plasma in vivo (Raz,
1972). -However, the affinity for prostaglandin binding 
was relatively low in comparison with the drugs which 
demonstrated species differences above. Paracetamol is 
only weakly bound to plasma proteins (20%) and its binding 
characteristics are similar in man and pig (Gazzard, et al3
1973). A calcium-binding protein from the gastro-intestinal 
tract showed only small differences in affinity but was 
remarkably similar in chicken, rat, pig and man, showing 
surprisingly little difference between such varied species 
(Hitchman & Harrison, 1972).
Displacement interaction
Some aspects of displacement interactions were described under 
the drug interaction section (section 1.1,6). Whilst all the above factors 
influencing the protein binding of drugs can alter the 
pharmacological activity of the drug, it is displacement 
of drugs from plasma binding sites that receives the 
greatest clinically-orientated attention. There are very 
few new drug ’data sheets’ issued, especially for anti­
inflammatory or anticoagulant drugs, which do not give 
some warning of possible displacement interactions.
Earlier in this section the transport role of plasma 
proteins for fatty acids was mentioned. As a result of an
increased metabolism, after exercise, the plasma 
concentrations of free fatty acids are elevated. Diazepam 
was observed to be displaced by elevated free fatty acid 
concentrations, but only in studies in vitro (Tsutsumi, 
et al3 1975). A study of rats in vivo has demonstrated 
that free fatty acid concentrations, elevated by exercise, 
have displaced warfarin and phenytoin from plasma binding 
sites (Gugler, et al3 1974). However, such displacement 
was not demonstrated with phenytoin in vivo and warfarin 
in vitro in man (Borga,.et al3 1978).
Displacement from plasma binding sites is of 
considerable importance with antibiotics and sulphonamides, 
where the free drug is the active form (Witzgall & Boyens, 
1964; Rolinson & Sutherland, 1965). A study of the 
ability of anti-inflammatory agents to displace urate 
from plasma proteins in vitro led to a clinical evaluation, 
as uricosuric agents,of four of the drugs studied 
(Whitehouse, et al3 1973). Subsequently an association 
between hypouricaemia and hyperbilirubinaemia was 
established demonstrating the ability of bilirubin to 
displace urate from plasma binding sites (Schlosstein, 
et al3 1973).
1.3 CARBENOXOLONE SODIUM
Carbenoxolone sodium is the first drug which has 
convincingly been shown to accelerate the healing of 
gastric ulcer (Avery Jones, 1968). This much-investigated 
drug has been the subject of six symposia (Robson &
Sullivan, 1968; Baron & Sullivan, 1970;, Avery Jones & 
Sullivan, 1972; Avery Jones & Parke, 1975; Beck, 1976;
Avery Jones, et al3 1978). Carbenoxolone sodium itself is 
a pure, semi-synthetic compound (Fig. 1.1), the hemisuccinate 
ester of 0-glycyrrhetinic acid (enoxolone), which is the 
aglycone of glycyrrhizic acid, one of the many constituents 
of liquorice root (glycyrrhiza glabra radix). .
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Fig 1.1 SRUCTURAL FORMULAE OF CARBSKOXOLOHE AMD RELATED COHPOUiTOS.
1.3.1 PHARMACOLOGY
The pharmacology of carbenoxolone. was originally 
described by Finney and Tarnoky (1960) and by Khan and 
Sullivan (1968). The anti-inflammatory activity of 
carbenoxolone was one third of that of hydrocortisone 
when given parenterally in a cotton pellet-granuloma. 
tes-t in rats. This activity was reduced following 
adrenalectomy but was not present following oral 
administration. However, an oral anti-inflammatory 
activity of carbenoxolone has subsequently been 
demonstrated,using the Freund’s Adjuvant arthritis test, 
with a potency about half that of phenylbutazone 
(Thornton, MacDonald, Sacra & Gottfried, unpublished 
observations). Carbenoxolone is known to be irritant 
when administered parenterally (Khan & Sullivan, 1968), 
thus it is possible that these earlier anti-inflammatory 
activities included a portion of adrenal stimulation by 
a counter-irritant principle (Cygielman, 1963).
Carbenoxolone has an aldosterone-like anti-diuretic 
activity in rats, causing a retention of sodium and water 
and an increased excretion of potassium (Khan & Sullivan, 
.1968). Other workers (Baron & Nabarro, 1968; Hausman & 
TArnoky, 1968) have demonstrated similar effects in man 
and stated that the effects were essentially resembling 
those of aldosterone. Porter (1970) observed that 
carbenoxolone- lacked an intrinsic activity but potentiated 
the activity of aldosterone on sodium transport in the 
isolated toad bladder. However, no such potentiation of 
aldosterone by carbenoxolone on sodium excretion was 
observed in adrenalectomised rats. Moreover, at the 
highest level of carbenoxolone used some reduction of 
potassium excretion was seen ( P o r t e r et al3 1974). Baron 
and colleagues (1969) demonstrated a reduced secretion 
rate of aldosterone, which was not renin-mediated, in a 
carbenoxolone patient and suggested that this might be 
due to a feedback inhibition of aldosterone secretion due 
to an intrinsic mineralocorticoid activity of carbenoxolone.
3The intracellular distribution of H-aldosterone 
was studied in the adrenalectomised rat kidney (Chakraborty, 
et al3 1970). The distribution of polar metabolites was 
not significantly altered, although there was an increase 
in unchanged aldosterone concentration. However, no 
change in the plasma concentration of free aldosterone 
was observed. Carbenoxolone has been shown to displace 
aldosterone from chicken plasma in vitro at a concentration of 
400 times the molar equivalent of aldosterone (Tarnoky,
1970). Hayes and Langman (1975) also demonstrated some 
displacement of aldosterone by carbenoxolone from human 
plasma in vitros at a carbenoxolone concentration 10 times 
therapeutic levels, but found that even with plasma from 
elderly patients, this displacement was clinically 
insignificant. Subsequently, where plasma binding and 
hepatic clearance of carbenoxolone was reduced in 
elderly patients, it was suggested that an increased 
aldosterone-like activity of carbenoxolone in the 
elderly may be due, in part, to a greater free drug 
concentration and consequent displacement of aldosterone 
(Hayes, et al3 1977).
Apart from this aldosterone-like activity, carben­
oxolone is a remarkably non-toxic drug,, the acute 
toxicity orally and intravenously in rats and mice is 
relatively low (Khan & Sullivan, 1968). Long term 
administration and carcinogenicity tests in mice, rats 
and dogs produced no signs of toxicity. Reproductive 
fertility studies in mice, rats and rabbits have not 
shown any adverse effects.
1.3.2 EXPERIMENTAL ULCER ACTIVITY
Experimental ulcer formation in the gastro-intestinal 
tract of animals is an extremely capricious model, 
especially in rodents. The first studies with carben­
oxolone on restraint-induced and 5-hydroxytryptamine- 
induced erosions were unsuccessful. However, Khan and^
Sullivan (1968), in experiments on diathermy-induced 
gastric ulcers from a specially designed electrocautery 
device, were able to demonstrate the beneficial effect of 
carbenoxolone in rats at dose levels of 25 and 50mg/kg 
orally. At the same time other workers (Dean, 1968;
Lipkin & Ludwig, 1968) were successful in treating 40/80- 
induced ulcers in rats, and restraint stress-induced 
ulcers in guinea pigs, with carbenoxolone. All these 
authors reported an increased gastric mucus production 
and suggested this as a possible mode of action of 
carbenoxolone. Subsequently Lipkin (1970) demonstrated 
an increased lifespan of the mucosal cells of the mouse 
gastric mucosa following treatment with carbenoxolone.
The increased lifespan of the mucOsal cells was thought 
to play a r6le in an increased mucus production.
The results with diathermy-induced ulcers have been 
confirmed recently, at a dose level of carbenoxolone of 
20mg/kg, in a comparison with an analogue, cicloxo'lone 
sodium (Thornton, MacDonald, Sacra & Gottfried, unpublished 
observations). These authors also demonstrated a 
preventative effect of carbenoxolone on stress-induced 
erosions, when given intraperitoneally at 60mg/kg. When 
ratsare dosed with this regimen there follows a short 
period of depression; it is possible that this prevention 
of stress-induced erosions is mediated via a central 
mechanism.
1.3.3 CLINICAL USE OF CARBENOXOLONE
In the first trial of carbenoxolone in gastric ulcer 
patients the drug was compared with the effects on in­
pat ients of various traditional remedies, such as bed 
rest and cessation of smoking. Carbenoxolone was found 
to be as beneficial to ambulant out-patients as the bed 
rest to in-patients (Doll, et al3 1.962). Subsequent trials 
confirmed the healing effect in man but demonstrated the 
side-effects of fluid retention and hypokalaemia in some
patients (Doll, et al3 1965). The incidence of side-effects 
in South African trials, which included long-term 
maintenance therapy, were less frequent than in British 
studies (Bank, et al3 1967; Bank & Marks, 1970; Bank, 1975). 
Treatment of the mineralocorticoid side-effects with the 
aldosterone-antagonist spironolactone reduced the fluid 
retention but also antagonised the beneficial effect of 
carbenoxolone (Doll, et al3 1968). In the same study 
thiazide diuretics proved to be capable of reducing the 
sodium and water retention without hindrance to the healing 
pattern. It is also interesting to note that the thiazide 
diuretics did not potentiate the potassium loss in this 
trial.
Treatment of duodenal ulcer with carbenoxolone as
Biogastrone1* tablets was unsuccessful (Doll, et al3 1962).
RHowever, the development of the Duogastrone capsule 
produced the first studies of healing of duodenal ulcers 
(Craig, et al3 1967; Hunt, 1968). The capsule is tanned 
gelatin designed to swell over 2|-3 hours in the stomach 
and rupture in the pylorus to deliver the carbenoxolone 
topically to the duodenum (Galloway, 1968; Lindup, et dls W o  
Lessof, 1975).
Following these early studies, the healing effect of 
carbenoxolone on duodenal ulcers has been confirmed world­
wide; Nigeria (Amure, 1970), Spain (Marcos Perez, 1970), 
Canada (Archambault, 1976), France (Villai*t, 1976), the 
United States (Hirschowitz, 1976) and Australia (Nagy, 1978)
Carbenoxolone has also been used to treat oesophagitis 
when formulated as an electuary (McAndrew & Foote, 1970; 
Silber, 1970; Atkinson,et dl3 1970). When reformulated,
R
for stability reasons, as a chewable tablet Pyrogastrone , 
carbenoxolone has-proved effective in double-blind studies 
(Davies'& Reed, 1975; Reed & Davies, 1978).
1.3.4 CARBENOXOLONE SIDE-EFFECTS ■
As stated earlier (section 1.3.1) carbenoxolone is 
relatively free from side-effects except for its aldosterone 
like activity. Transient increases in hepatic transaminases 
have been observed in some patients a.nd following long­
term treatment in the rat (Cliff, 1968; Baron & Nabarro, 
1968; Hausman & T&rnoky, 1968; Sullivan, 1972). These 
changes are not thought to be related to pathology and 
occur with other drugs excreted via the bile.
The retention of sodium leading to oedema was 
recognised from the earliest clinical trials (Doll, et al9 
1965) but has been managed by concomitant therapy with 
thiazide diuretics (Doll, et al3 1968). The hypokalaemia 
does not appear to result from urinary loss and is not 
associated with total body potassium flux (Edmonds &
Tomkins, 1975). These authors have suggested that the 
hypokalaemia is due to a small continuous loss from the 
gastro-intestinal tract which is demonstrated by changes 
in colonic potential difference (Tomkins & Edmonds, 1975). 
The administration of bendrofluazide with carbenoxolone 
did result in a marked loss of total body potassium, but 
not when amiloride was given as a diuretic. Failure of 
the kidney to excrete sodium from high plasma concentrations 
as an ’escape' mechanism is possibly the idiosyncratic 
origin of the occurrence of side-effects in only some 
patients (Edmonds & Tomkins, 1975). Side-effects are 
more prevalent in elderly patients a,nd in those with 
renal or hepatic failure, being contraindicated in the 
latter two cases. Comparison between normal and elderly 
patients has demonstrated a reduced plasma clearance rate 
and total binding capacity, suggesting that an increase 
in free carbenoxolone may, in part, account for the 
increased incidence of side-effects in the elderly (Hayes, 
et al3 1977). '
In cases of prolonged carbenoxolone therapy without
adequate patient monitoring, especiklly in elderly 
patients, the side-effects have consequently been severe 
(Davies, et al3 1974).
1. 3. 5 MODE OF ACTION OF CARBENOXOLONE
From the earliest clinical studies it was considered 
that carbenoxolone exerted its mode of action in healing 
peptic ulcer by augmenting the defensive factors rather 
than inhibiting the aggressive forces (Avery Jones, 1968). 
Carbenoxolone does not affect gastric motility (Connell 
& Loane, 1968) or acid and pepsin secretion (Ottenjann & 
Rosch, 1970; Berstad, et al3 1970; Ba.ron, 1977).
Increase in gastric mucus secretion has been seen 
in cats, and in man, following treatment with carbenoxolone 
(Goodier, 1968; Johnson, 1968). Lipkin (1970) has 
demonstrated an increased lifespan of gastric mucosal 
cells, a possible factor in the increased production of 
mucus.
Torrna and colleagues (1975) have also demonstrated *
the ability of carbenoxolone pretreatment, in the dog, 
to reduce, the cell loss from the gastric mucosa in 
aspirin-induced gastritis in situ. Studies of gastric 
epithelial cells in carbenoxolone-treated patients have 
subsequently confirmed Lipkin1s original findings in 
mice (Croft, 1973; Klein, et al3 1975). It is possible 
that the membrane stabilisation of carbenoxolone plays 
a role in the decreased rate of turnover of gastric 
epithelial cells (Parke, 1976; Symons, 1976).
Animal studies on glucuronyl transferase activity 
of the gastric mucosa and the content of hexosamine, 
fucose and sialic acid in mucus have provided some 
pharmacological evidence for the increase in-mucus 
secretion following carbenoxolone treatment (Shilling!ord, 
et al3 1973). Studies on rat duodenal mucosa did not show
the same activity, but the animals were dosed orally so
that most of the drug would have been absorbed from the
stomach mucosa and thus not able to exert a topical effect
in the duodenum. In a further study, the rate of
3incorporation of H-N-acetylglucosamine and other sugars 
into rat and ferret stomach glycoproteins in vitro was 
increased following oral treatment with carbenoxolone for 
seven days prior to the study (Shillingford, et al3 1974). 
Again carbenoxolone did not show any effect on the 
duodenal mucosa when given orally to these animals. The 
addition of carbenoxolone to stomach portions in vitro, 
of previously untreated animals, inhibited the incorporation 
of the sugars into gastric glycoproteins. This is not 
surprising because free carbenoxolone is a potent uncoupler 
of oxidative phosphorylation (Whitehouse, et al9 1987).
The increase in N-acetylglucosamine incorporation into 
the rat stomach mucosa has been confirmed where the 
animals received a bolus oral dose of carbenoxolone in 
addition to an equal dose via the drinking water (Thornton, 
MacDonald, Sacra & Gottfried, unpublished observations).
In clinical studies a reduced rate of N-acetylglucosamine 
incorporation is associated with gastric ulcer and gastric 
cancer. Treatment with carbenoxolone has restored this 
rate of incorporation (Johnston, et al9 1975).
The aldosterone antagonist, spironolactone, is known 
to inhibit the healing activity of ca„rbenoxolone (Doll, 
et dlj 1968). In animal studies, pretreatment for seven 
days with spironolactone has been shown to inhibit the 
incorporation of N-acetylglucosamine and galactose into 
rat gastric mucosa, the opposite effect of carbenoxolone 
(Johnston, et al9 1975).
Carbenoxolone protects the gastric mucosa against 
bile salt-induced damage in human patients and in gastric 
pouches in dogs (Cross & Rhodes, '1972; Ivey & Gray, 1973). 
Further studies in dog pouches have demonstrated the .
ability of carbenoxolone to reduce the hydrogen ion back- 
diffusion across the gastric mucosa (Thompson, et al9 1975). 
Clinical studies have correlated the prevention of 
hydrogen ion back-diffusion with an increased mucus 
secretion as measured by N-acetylneuraminic acid content 
(Domschke, et al3 1975). Aspirin-induced damage to gastric 
mucosa results in an increased permeability to the back- 
diffusion of hydrogen ions which may be monitored by a 
fall in mucosal potential difference (Overholt & Pollard, 
1968). Clinical studies have shown the beneficial effect 
of carbenoxolone in preventing the lowering of gastric 
potential difference induced by aspirin (Hossenbocus & 
Colin-Jones, 1975).
Although the principal action of carbenoxolone seems 
to be mediated via the gastric mucosa and mucus synthesis, some . 
inhibition of pepsin activity has been demonstrated iii 
vitro (Henman, 1970) and in vivo (Berstad, 1972). Birnbaum 
and Karmeli (1975) demonstrated a reduction of uropeptic 
secretion following carbenoxolone treatment of both rats 
and man. Similarly a reduction in pepsin secretion in 
man following carbenoxolone therapy was observed (Walker 
& Taylor, 1975). These authors demonstrated a fall in 
pepsin secretion in response to pentagastrin stimulation, 
a reduction in the proportion of Pepsin 1 and a reduction 
in the minimum secretion of pepsins.
1.3.6 DISPOSITION AND METABOLISM *
14
Early studies of carbenoxolone in the rat with C
in the succinate moeity revealed that the drug was
hydrolysed to enoxolone after oral administration (Parke,
31968b). Subsequent studies were undertaken with H-
3enoxolone and with carbenoxolone doubly labelled, H in
14the triterpenoid and C in the succinate moeities. After 
hydrolysis to enoxolone this was absorbed rapidly from the 
stomach, conjugated in the liver as glucuronide and 
sulphate and excreted almost entirely in the bile. Further
hydrolysis occurred in the gastro-intestinal tract to
leave enoxolone in the faeces (Parke, et al3 1963; Iveson
et al3 1971). Enoxolone was shown to undergo enterohepatic
14circulation. When C-carbenoxolone was given orally,
14
60-75% of the C was excreted as ca.rbon dioxide,
presumably from the succinate hydrolysis followed by-
metabolism via the citric acid cycle (Iveson, et al3 1966)..
Less than 20% of the radioactivity was detected in the
urine.- There is evidence to suggest that the hydrolysis
of carbenoxolone is due to the microflora of the rat
gastro-intestinal tract and not to mammalian tissue
14hydrolysis, because COg excretion is less following 
intraperitoneal administration and rat caecal contents 
have been shown to hydrolyse carbenoxolone (Iveson, et al3
1971). The major biliary metabolites following oral 
administration to the rat are the 3-sulphate, 30-glucuronide 
and 3,30-diglucuronide of enoxolone. However, -when 
administered by the intraperitoneal route to rats, or 
orally to rats pretreated with orally-administered anti­
biotics, the principal biliary metabolite is the 30- 
glucuronide of carbenoxolone. In man, ferret and the
squirrel monkey the principal metabolite is the 30-glucuronide
14of carbenoxolone, the squirrel monkey excretes more C-
14
carbenoxolone in the faeces and less CO^ than man (Iveson, 
et al3 1971; Shillingford, Lindup & Parke, personal 
communication).
When carbenoxolone is orally administered to man it 
is rapidly absorbed from the stomach resulting in blood 
concentrations of about 20 jng/rnl after 1 hour. This 
represents about 80% of the 100 mg dose in the plasma 
(Downer, et dl3 1970). The rapid absorption of carben­
oxolone may be interpreted as a measure of both the 
lipophilicity of this high molecular weight sodium salt, 
which is insoluble at gastric pH,- and of its affinity 
for proteins (Parke, 1972). Recent rat studies in vitro 
and in situ have confirmed that carbenoxolone is absorbed 
in both ionised and unionised forms with extensive
absorption on to the proteins of the gastric mucosa 
(Bridges, et al3 1976).
Following absorption, carbenoxolone is virtually
confined to the plasma, liver, bile and gastro-intestinal
tract due to its hfgh affinity for protein binding.
With less than 2% appearing in the urine it is evident
that there is considerable enterohepatic circulation
(Downer, et al3 1970; Parke, et al3 1972). Studies with 
14C-carbenoxolone in the rat have not shown association 
with kidneys, fat, brain or other tissues. Furthermore, 
when administered by the intraperitoneal route, the 
drug was found to be associated with the gastric mucosa, 
suggesting a special affinity for carbenoxolone at that 
site (Parke, 1972).
Investigations using plasma from various species 
have shown that carbenoxolone is almost totally bound 
to plasma proteins in circulation (Chakraborty, et al3 
1970; Parke & Lindup, 1973). At concentrations of up to 
91 jig/ml carbenoxolone was more than 99% bound to plasma 
proteins in the rat, dog, monkey and man. Clinical 
studies have since revealed maximum human plasma, 
concentrations, after repeated therapy, to be around 
100 pg/ml and up to 20 p.g/mi after a single 100 mg dose 
(Baron, et at3 1975).
Carbenoxolone is bound principally to albumin but 
it is also associated to a small extent with and a^ 
globulins (Parke & Lindup, 1973). The albumin binding
7
has a high affinity of the order 10 1/mol at the primary 
sites (n^ = 2 ) .  A conformational change of the albumin 
is not suspected but further sites are available with an 
affinity of 2 x 10^ 1/mol (n^ = 6).
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MEASUREMENT OF CARBENOXOLONE BINDING IN VITRO
2.1 INTRODUCTION
2.1.1 METHODS OF MEASUREMENT OF PROTEIN BINDING
In all of the various physico-chemical techniques used 
to measure protein binding (Table 2.1) one of three basic 
parameters is being determined:
i) the concentration of free ligand;
ii) perturbation of the bound ligand;
iii) perturbation of the binding protein.
Early or ’classical’ methods of measurement of protein 
binding consisted of equilibrium dialysis, ultrafiltration 
and electrophoresis.
Equilibrium dialysis (Klotz, et al3 1946) is by far the 
most commonly used method to study protein binding (Bush & 
Alvin, 1973). The system consists of a semi-permeable 
visking membrane separating a protein solution from a drug 
solution. After a given period of time the drug equilibrates 
between the two compartments, whence the drug concentration 
in the protein-free compartment represents the level of free 
drug. This method relies on the assumption that the drug is 
in a state of dynamic equilibrium with the protein and that 
the free fraction of drug is in equilibrium between the two 
compartments. The disadvantages of the method lie within 
these assumptions, that a Donnan membrane effect may
prevent equilibrium across the membrane being achieved or that 
the drug may bind to the membrane itself. In'practice a 
considerable length of time (up to 48 hours) may be required 
to establish the equilibrium,introducing additional risks of 
bacterial contamination and degradation of the protein and/or 
drug.
'Ultrafiltration (Rehberg, 1943) is an attempt to achieve 
the results of equilibrium dialysis more rapidly. The drug- 
protein complex is subjected to an increased pressure,
Table 2.1 SUMMARY OF COMMON METHODS OF MEASUREMENT OF 
LIGAND-PROTEIN BINDING
Estimation of free ligand concentration
a) Distribution between phases - equilibrium dialysis
- ultrafiltrat'ion
- dynamic dialysis
- partition
- gel filtration
b) Competition with bound indicator - optical spectroscopy
- fluorescence
- nuclear magnetic resonance
Perturbation of properties of bound ligand
a) Optical spectroscopy
b) Optical rotation
c) Fluorescence
d) Nuclear magnetic resonance
Perturbation of properties of binding macromolecule
a) As above
b) Electrophoresis
c) X-ray crystallography
either directly or by ultracentrifugation, across a semi- 
permeable membrane whereby a small aliquot of the vehicle, 
containing the free concentration of drug, is forced 
across the membrane. This method has obvious advantages 
of time saving over equilibrium dialysis but share's the 
problem of membrane binding and, furthermore, induces a 
change in the protein concentration which may alter the 
binding being measured.
Electrophoresis (Alberty & Martin, 1.951) of plasma- 
ligand (or serum-ligand) complexes will produce a 
qualitative analysis of binding but does not lend itself 
readily to interpretation of quantitative data. For rapid 
attainment of qualitative data a crossing electrophoresis 
technique has been introduced (Bickel & Bovet, 1962).
These ’classical’ methods have been improved since 
the advent of radio-chemically labelled drugs enabling 
studies to be carried out at therapeutic concentrations 
(Meyer & Guttman, 1968).
Gel filtration3 a more, recent method (Porath & Flodin, 
1959; Flodin, 1961) uses cross-linked polysaccharides 
(Sephadex) to separate chromatographically the protein- 
ligand complex from the free drug. Results are similar 
to those from dialysis methods without the problems of 
membrane binding, Donnan effects and time factors. The 
disadvantages of gel filtration include an interaction 
between the drug and Sephadex, and a dilution of the 
protein-ligand complex (Kucera & Bullock, 1969; Meyer & 
Guttman, 1968). To prevent interaction between the ligand- 
protein complex and the Sephadex, elution is carried out 
with a solution of the drug in place of the usual buffer 
(Hummel & Dreyer, 1962).
The binding of ligands to protein can induce changes 
which are measureable by various spectropho tome trie methods.
Solutions of albumin possess a native fluorescence which 
may be quenched by the binding of a ligand (Chignell, 1969). 
This quenching is proportional to the molar ratio between 
the ligand and protein, thus titration of the ligand with 
the protein enables the evaluation of free and bound drug 
concentrations (Chignell, 1972a). However, where more than one 
class of binding site is present, the sites with lower 
affinities may be masked (Chignell, 1972b). The use of 
this method is limited by the fact that fluorescence 
quenching measurements may only be made on single protein 
fractions.
When warfarin binds to human serum albumin, the 
fluorescence quantum yield of the drug increases eight-fold and with 
rat serum albumin thirteen-fold (Chignell, 1970). Thus 
the binding of warfarin,and other fluorescent drugs, such 
as tetracyclines may be monitored by this method (Popov, 
et al3 1972). The obvious drawback of this technique is 
that the ligands must have native fluorescence when bound 
to proteins.
A fluorescent probe is a ligand which possesses
negligible native.fluorescence in the free state but
strongly fluoresces when bound to a macromolecule (Weber,
/
1952). A fluorescent probe also has a low intrinsic binding 
affinity and is quantitatively displaced by a second ligand, 
in proportion to the affinity of the second-ligand. This 
technique is rapid and does not suffer from any of the 
problems of dialysis or gel filtration. Fluorescent probes 
may also be used to reveal data on the nature of the binding
sites (Chignell, 1972a). However, data which is obtained"
for drug binding is of an indirect nature and must rely on
the drug binding to the same site as the probe.
An analogous series of measurements to the above 
fluorescence techniques may be made using ultraviolet light
absorption. Westphal (1961) and Ryan (1968) have
used the technique of ultraviolet light difference 
spectroscopy, whilst Moriguchi and colleagues 
(1968a, 1968b) have used an ultraviolet spectro- 
photometric probe. However, Zia and Price (1975)
more recently introduced studies with . a spectro- 
photometric probe based on the fluorescence work 
of Jun and colleagues (1971). The use of ultra­
violet spectrophotometric measurements share both 
the advantages and disadvantages of the fluorescence
methods but are superior under conditions whereby
fluorescence of a ligand does not occur, or
fluorescence changes are . associated with photoxidation
(Zia & Price, 1975).
Circular dichroism is a technique which relies 
upon the binding of certain ligands to protein 
which induces extrinsic Cotton effects (Blout, 1964) 
which are measurable on spectropolarimeters (Chignell, 
1968). These changes may be utilised to follow
ligand binding in a three dimensional form. However, 
in order to yield useful data the ligand needs 
to contain a chromophore which absorbs ultraviolet 
light, and must be bound to the protein in an
asymmetrical fashion (Ikeda & Hamaguchi, 1969).
This method shares the advantages of other spectro­
photometric studies over the classical methods in
that it is rapid and does not -.involve membrane 
binding or dilution changes. However, the method
requires specific equipment which is expensive.
illuclean magnetic resonance (nmr) spectroscopy is a 
refined technique which can provide qualitative data 
on the exact nature of the functional groups 
involved in binding (Jardetzky, 1964; Jardetzky & 
Wade-Jardetzky, 1965; Fisher &• Jardetzky, 1965).
One drawback of the .method is that the exact 
amino acid sequence of the protein under study
must be evaluated and the peaks corresponding to 
protons in given amino acids established, whereby
changes in these peaks are seen to correspond
to binding interaction (Davison, 1971).. It is only 
possible to obtain qualitative binding from nmr 
studies and, again, the necessary equipment is 
expensive.
Two more recent innovations of measurement are 
dynamic dialysis and dialysis in vivo, essentially 
modifications of the classical equilibrium dialysis.
Dynamic dialysis is an attempt to reduce the 
time factors of equilibrium dialysis. The method
is based on the assumption that the rate of
disappearance of the ligand from the external
phase is proportional to the concentration of the
unbound species (Meyer & Guttman, 1968a). Studies
with dynamic dialysis have yielded results comparable 
to ultrafiltration and .equilibrium dialysis (Meyer
& Guttman, 1970). However, although the technique 
is described as ’rapid', the apparent permeability 
rate for the ligand has to be determined (2h)
prior to use and the model is then observed for
up to 9 hours (Meyer & Guttman, 1970).. The other
disadvantages are similar to equilibrium dialysis, 
being visking tube binding and Donnan membrane 
effects. The method has been little used to date.
All of the previous methods evaluate ligand-protein binding 
in vitro and are thus non-physiological. However:, equilibrium
dialysis has been adapted to a situation in vivo using an 
intraperitoneally implanted sac, allowing aliquots to be 
withdrawn for determination of the free ligand concentration 
(McQueen, 1968). However, this technique may only be 
useful for repeated measurements in large animals such as 
sheep (McQueen & Wardell, 1971).
Various other methods of measuring protein binding 
have been tried but have received limited use and are 
thus not established. Measurement of changes in biological 
activity are suitable only for antibacterial agents, 
similarly increases in solubility, changes in pH, refractive 
index, conductivity and EMF are only suitable for certain 
ligands and will yield only limited binding data (Goldstein, 
1949; Meyer & Guttman, 1968; Steinhardt & Reynolds, 1969; 
Davison, 1971; Klotz, 1973).
2.1.2 INTERPRETATION OF DATA
Methods of presentation of ligand-macromolecule data 
are diverse. A simple graphical plot of degree of binding 
versus ligand or protein concentration reveals the saturation 
point of binding only. However, where a protein mixture 
such as plasma is used it may be the only valid interpretation. 
As Goldstein (1949) pointed out, the statement that a given 
fraction of drug is bound is meaningless without reference 
to the unbound concentration and protein concentration.
Where a pure protein fraction has been used at an 
accurate concentration then estimations of three basic 
parameters may be made (i) the number of classes of binding 
site; (ii) the number of molecules of ligand bound at each 
class of site; (iii) the apparent affinity of the ligand 
for the binding sites.
The law of Mass Action may be applied to parameters 
measured, thus the affinity constant, k, of a ligand for 
a protein may be defined as: ' .
k = __□!— S J _  or [p D] • = k [p] Cd J  (1)
CpD CDf]
Where CpI is the protein concentration, CD f 1 is 
the free ligand concentration and [P D] is the bound 
ligand-protein complex, then
__ moles bound drug _    fP PI (2)
total moles protein £P DJ + [P]
k rDLutl
1 + k [ D „ ]
(3)
f
Where more than one binding site exists and where n
equals the number of identical independent sites,
nk [Df ]
r + r _r= r . rs -----  (4)
1 2 l +■ k [Df ]
thus equation (4) may be rearranged to give
1 = n + n k T D fT' (5)r
A direct plot of r versu^ D^]is analogous to the Michaelis- 
Menton plot and is a hyperbola with r - n at the plateau 
andCb.pIt 1/k when r = n/2'.
A reciprocal plot of 1/r versus 1/D^ is analogous to 
a Linweaver-Burke plot and is a linear transformation from 
which n and k can be estimated from the slope (1/kn) and 
intercept (1/n). However, low values of 1/r are spread 
poorly.
Scatchard (1949) performed an alternative rearrangement 
of equation (4) to
r/ ] = nk - rk (6)
By plotting r / [ Df ] versus r, the abscissa intercept is 
n, the ordinate intercept nk and the slope k. The Scatchard 
plot spreads the data well and is generally the method of 
choice (Meyer & Guttman, 1968). It is certainly the most
commonly used method of analysis which facilitates 
comparison between workers.
Rosenthal (1967) produced a rearrangement of equation
(4) for use where the protein concentration was not known 
and described a plot similar to that of Scatchard (1949).
C d Jb = n k [ P ]  - k [ D b ] (7)
LDf J
Where £ ] is the bound ligand concentration. A plot
of £ *] / versus (total ligand concentration)
is linear and allows the estimation of n QP'] from the 
abscissa intercept, nk [p] from the ordinate intercept 
.and k from the slope. The Rosenthal method is still not 
as widely used as that of Scatchard.
All of these methods of determining binding parameters 
rely on a linear transformation, but where more than one 
class of binding site is present then differing affinities 
for each site will result in a curvi-linear plot. Because, 
of the reliance of these methods on a standard uniform 
binding pattern, extrapolation in the presence of more than the 
one class of site does not bear the same validity as with 
one class system (Madsen & Robertson, 1974).
2.1.3 ' PRESENT EXPERIMENTS
Estimation of the protein binding of carbenoxolone 
was undertaken using three methods. "Equilibrium dialysis 
and ultrafiltration were chosen as classical methods to 
allow comparison with previous studies (Lindup, 1971). 
Fluorescent probe studies were carried out to investigate 
a newer methodology capable of rapidly yielding data on 
several ligands without requiring the use of radio-labelled 
materials. Both bovine and human crystalline albumins 
were used to allow correlation with other workers and to 
provide a basis for comparison with the clinical situation. 
Interpretations of binding data were made using the Scatchard 
equation, again for reasons of comparison.
2.2 EXPERIMENTAL
The carbenoxolone (Biorex Laboratories Ltd.) used 
throughout this and subsequent chapters was the disodium 
salt. Phenylbutazone (Biorex Laboratories Ltd.) and 
warfarin sodium (Gehardt Penick) were also used. The 
protein fractions used were crystalline Cohn fraction V 
bovine (BDH) and human (Calbiochem) serum albumins.
3
All samples containing H-carbenoxolone were
determined by scintillation counting in Triton-toluene
scintillant using a Packard Tri-carb 3320 scintillation
counter. Verification - of counting efficiency was
made and the specific activity and radiochemical purity 
3
of the H-carbenoxolone determined prior to, and during, 
experimentation by scintillation counting and thin layer 
chromatography.
2.2.1 EQUILIBRIUM DIALYSIS
Factors affecting equilibrium dialysis. Pilot tests were 
carried out to establish (i) whether carbenoxolone w a s ■ 
bound to the dialysis tubing, and if so procedures to 
reduce it, (ii) length of time necessary to obtain 
equilibrium, and (iii) internal phase volume size.
Visking tubing (Scientific Instruments Ltd.) was used 
at k inch and I inch widths in 12 cm lengths. Carbenoxolone 
binding to the membrane was estimated as follows: dialysis
sacs were cut into small pieces and boiled in 25 ml 0.1M 
NaOH for 30 minutes. ' The mixture was filtered and the 
portions of visking sac rinsed. The filtrate was evaporated 
to dryness and the precipitate was taken up in 1 ml distilled 
water whence aliquots of 0.2 ml were used to estimate the 
carbenoxolone concentration.
The following solutions were used to pretreat the 
visking sacs: NaHCO^ as a 5% w/v solution; buffers; pH
7.0 BDH tablets; pH 7.4 0.1 M phosphate. Di potassium ethylene
diamine tetra acetic acid (K^EDTA) was used as a 10 mM 
aqueous solution.
Pretreatment of visking tubing commenced with
i) storing at 90°c in sodium bicarbonate for 1 hour, rinsing 
in distilled water and storing in pH 7.0 buffer overnight 
at 4°C; ii) bicarbonate as above, then soaking in KQEDTA
r\
for 1 hour prior to storage at pH 7.4 overnight at 4 C;
iii) washing procedure' as in ii) with storage in phosphate 
buffer containing 50 jig/ml unlabelled carbenoxolone.
Dialysis was carried out for 18 and 24 hours with 
stationary internal and external phases. This was repeated 
with air agitation of the external phase for 24 hours. 
Internal phase volumes of 5.0 and 0.5 ml were used. Dialyses 
with water, saline and 0.1 M phosphate buffer were carried 
out to determine the equilibration time.
3Bind.ing of U-carbenoxolone to bovine serum albumin. Dialysis
experiments were performed in duplicate. The internal phase
-4was 0.5 ml bovine serum albumin at 10 M in 0.1 M phosphate 
buffer at pH 7.4. The external phase was 5 ml of buffer 
only. Visking tubing was \ inch width. The tubing was
pretreated by storing at 90°C in 5% NaHCOg for 1 hour,
then in 10 mM aqueous KQEDTA for 1 hour and stored overnight at
4°C in 0.1 M phosphate buffer at pH 7.4. ^H-Carbenoxolone had
a specific activity of 7.36 mCi/g and was used as a methanolic solution.
Aliquots of the carbenoxolone solution were placed 
in teflon-stoppered tubes and evaporated in a water bath.
The external phase was added to each tube and mixed for 
30 minutes to establish complete dissolution. Samples of 
the external phase were taken for determination of the 
initial carbenoxolone concentration. Carbenoxolone 
concentrations of 10 to 500 Mg/mi were used. The internal 
phase was then pipetted into the dialysis sacs which were
placed in the stoppered tubes on a rotary mixer for
2,4 hours at 4°C. After the period of dialysis, 0.2 ml 
aliquots of each phase were used to determine the 
carbenoxolone concentration.
The influence of 'phenylbutazone on carbenoxolone binding. 
Equilibrium dialysis was repeated with unlabelled phenyl­
butazone added to the external phase at an equimolar 
concentration to the carbenoxolone. Determinations 
were carried out in duplicate.
2.2.2 FLUORESCENT PROBE TECHNIQUE
These studies were based on the technique of Jun and
colleagues (1972). The fluorescent probe used was 1-anilino-
-38-naphthalene sulphonic acid (ANSA, Sigma) as a 10 M 
solution in methanol. Bovine and human serum albumins were 
used in 0.05 M, and initially in 0.1 M, phosphate buffer at 
pH 7.4. Carbenoxolone, phenylbutazone and warfarin were 
used as 0.1 M methanolic solutions. The methanol was 
redistilled a r - grade and the water was double-distilled 
from glass.
The fluorescence intensities of the bound probe, ANSA,
were measured on a Baird Atomic FP100 Fluoripoint spectro-
fluorimeter X activation 380 nm and A fluorescence 470 nm
(uncorrected instrumental values). The instrument was set
on high sensitivity with 10 nm slit widths. The serum
solutions (2.0 ml) in a quartz cuvetle were titrated with
the fluorescent probe solution (1-10 p.1 aliquots) using an
automatic micropipette (Finnpipette). Titrations were
performed with two protein concentrations, 0.1 and i.O mg/ml and
with the buffer alone. Where drug binding was investigated
-4the drug was added at 10 M to the albumin solution prior 
to titration with the fluorescent probe.
The fraction of probe bound was calculated by the 
method of Brand and colleagues (1967).
x _ (Io Ji> - 1
* " (Ib / If) - 1
where the fraction of probe bound, 1^, is the 
fluorescence intensity of the probe in the high protein
concentration, I is the fluorescence intensity of theo
probe in the low protein concentration and 1^ is the 
fluorescence intensity of the probe in the buffer alone. 
Subsequently the Scatchard (1949) equation was applied.
ANSA was titrated with both bovine and human serum 
albumins in 0.05 M phosphate buffer alone,and in the 
presence of carbenoxolone sodium, phenylbutazone and 
warfarin.
2.2. 3 ULTRAFILTRATION TECHNIQUE.
This method was basically that of Keller and colleagues
(1966). Bovine and human serum albumins were used at 
10~4 M and 1.49 x 10~4 M (1%) in 0.1 M phosphate buffer at 
pH 7.4. Dialysis tubing was 24/32 inches (Scientific 
Supplies Ltd.) and was pretreated as for equilibrium dialysis 
(section 2.2.1). For centrifugation Toribara tubes (Toribara, 
et at* 1957) were used as modified by Lindup (1971). These 
consisted of 10 cm Pyrex tubes with a sintered disc 
(porosity 1) at 2.5 cm. Phenylbutazone and warfarin were 
used as 0.1 M solutions in methanol.
3Measurements of binding of H-c'arbenoxolone to bovine 
serum albumin were made at concentrations of albumin between 
0.1 and 10%. Carbenoxolone was used up to 500 jig/ml. The 
binding of carbenoxolone to the dialysis sacs was determined 
as in section 2.2.1.
The drug-protein complex was made up in bulk and 5 ml 
aliquots were equilibrated in 15nl teflon-stoppered tubes on a 
rotary mixer for 30 minutes. Aliquots of 4 ml were then 
pipetted into 20 cm lengths of dialysis tubing which were
rested on the glass sinter in a U shape with the 
ends uppermost. The Toribara tubes were placed in 
100 ml polypropylene tubes for centrifugation 
in an MSE ’Mistral' centrifuge at 4°C for 2 hours at 
680 g . The ultrafiltrate was approximately 5% of the
original volume. The original carbenoxolone concentration 
was determined from the remaining 1 ml aliquot of drug- 
protein complex from the teflon-stoppered tubes. Where a 
second drug was used, it was added to the teflon-stoppered 
tubes as a methanolic solution and the solvent evaporated 
prior to the addition of the protein solution.
The concentration of unbound carbenoxolone was
calculated from the equation (Keller, et a'll 1966) where 
j^D^is the initial molar concentration of carbenoxolone, 
and dpm the radioactive disintegrations per minute.
Td  1 = Td  1 x net dpm/ml filtrate 
L L npt. dnm/ml sac r».nnt.<et p  co tents 
The results were plotted using the method of Scatchard (1949)
The influence of phenylbutazone and warfarin on carbenoxolone
binding. The carbenoxolone concentrations used were based on
the maximum therapeutic blood level and a concentration which
3was 50% bound in this system. At the lower H-carbenoxolone 
level of 20 pg/ml, phenylbutazone and warfarin were added at 
a concentration of ten times the molar equivalent of carben­
oxolone but at the higher carbenoxolone level of 450 jtig/ml, 
equimolar concentratipns of the interacting drugs were used.
2.3 RESULTS
3Measurement of the counting efficiency of H was
3
confirmed using standard Ho0. The radiochemical purity 
3of the H-carbenoxolone used was 94.1% with 5% being
identified as 18-/3 glycyrrhetinic acid. This was of a similar purity
to the carbenoxolone standard used. The radiochemical 
3purity of H-carbenoxolone was unchanged by storage as an 
aqueous solution at 4°C for 3 months.
2.3.1 EQUILIBRIUM DIALYSIS
Factors affecting equilibrium dialysis. Untreated visking 
membrane bound significant levels. (12.3 jig/sac) 
of carbenoxolone from a saline solution, although this was 
reduced (5.9 ug/sac) when protein was present (0.01% 
bovine albumin). However, treatment of the visking with 
bicarbonate and EDTA also significantly reduced the binding 
(4.8 pg/sac, P<0.02), whilst pretreatment with unlabelled 
carbenoxolone was unsuccessful.
Even within various stages of agitation equilibrium 
was not achieved within 24 hours until a rotamix was used 
with an internal phase volume of 0.5 ml and an external 
phase of 5 ml.
Binding of ^H-carbenoxolone to bovine serum albumin (Table 2.2,
Fig. 2.1). A linear concentration-dependant binding was
observed between carbenoxolone and bovine serum albumin at
-4 *10 M (correlation coefficient = 0.994). Maximal binding
was only 80-85% at a carbenoxolone concentration of 10~50pg/ml, whilst at
500 pg/ml carbenoxolone was only 50% bound. A Scatchard
plot was linear (correlation coefficient - 0.973) which
may be interpreted as representing only one class of binding
site with approximately 9 binding sites per molecule and an
3affinity constant of the order of 8.9 x 10 1/mole.
The bound concentration of carbenoxolone was slightly 
decreased in the presence of an equimolar concentration of 
phenylbutazone, the effect being greatest at the highest
TABLE 2.2 BINDING OF 3H-CARBENOXOLONE SODIUM TO BOVINE
SERUM ALBUMIN 
Initial concentration
(yttg/ml)
Final concentration 
Internal Externa.1 
(x10*“4M)' (xlO ~5M)
. Degree of binding 
(%)
10 1.5 0 * 99.9
50 7.1 1.1 87
100 13.5 2. S 83
250 29.3 11.4 72
500 47.2 34.2 58
* not detectable within background limits
Equilibrium dialysis was carried out for 24 hours at 4°C 
-4with 10 M bovine serum albumin in 0.1 M phosphate buffer 
at pH 7.4. Internal phase volume was 0.5 ml and external 
volume 5 ml. Results are the mean of duplicate observations.
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Fig 2.1 SCATCHARD PLOT OF 3H-CARBENOXOLONE BINDING TO 
BOVINE SERUM ALBUMIN, FROM EQUILIBRIUM DIALYSIS.
Where Vn= mole of bound carbenoxolone per mole of albumin 
Ac molar concentration of free ligand.
Dialysis was carried out in 0.1M phosphate buffer at pH 7*4 
and 4 C for 24 hours.
Linear correlation coefficients 0.973 
kQ= 8« 9x 10*^  1/ mole
n1=9
Each point represents the mean of 6 observations<
concentration of carbenoxolone (Fig. 2.2). The 
Scatchard plot reveals a linear relationship for each 
group but with differing slopes. The presence of 
phenylbutazone has effectively reduced the number of binding 
sites available to carbenoxolone from 9 to 6 but resulted
3
in an apparent increase in affinity from 9.0 to 13.3 x 10 
1/mole.
2.3.2 FLUORESCENT PROBE TECHNIQUE
The effect of buffer molarity. The fluorescence intensity of the 
probe ANSA, when bound to bovine serum albumin at a concentration 
of 1.0 mg/ml, was higher in 0.1 M phosphate buffer than 
in 0.05 M phosphate buffer. Despite the fact that the concentration 
of albumin was constant in both cases, the probe was 
apparently bound to a larger extent in the buffer of 
greater molarity, producing an increased fluorescence
intensity, suggesting that more binding sites were 
available. The buffer molarity was maintained at 0.05 M 
throughout the remaining studies.
The binding of carbenoxolone3 phenylbutazone and warfarin to 
bovine serum albumin (Figs. 2.3 - 2.5). Titration of ANSA with 
bovine serum albumin at a concentration of l.Omg/ml revealed a linear 
relationship between probe concentration and fluorescence 
intensity, indicating an excess of binding sites. However, 
titration of the probe with bovine serum albumin, at a concentration of 
0.1 mg/ml, demonstrated a saturation of the binding sites, 
indicated by a plateau on the curve of fluorescence versus 
probe concentration (Fig. 2.3). Addition of the three 
drugs, carbenoxolone, phenylbutazone and warfarin, to the 
lower protein concentration caused displacement of the 
probe demonstrated by the reduced fluorescence in Fig. 2.4. The 
greatest displacement was caused by carbenoxolone and 
phenylbutazone, with warfarin displacing the probe to a 
lesser extent. Scatchard plots (Fig. 2.5) were linear for 
each drug and for the probe itself, which may be interpreted 
as evidence of the presence of only a single class of binding
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Fig 2,2 SCATCHARD PLOT OF 3H-CARBENOXOLONE BINDING AND 
THE INFLUENCE OF PHENYLBUTAZONE
Carbenoxolone (O) and in the presence of phenylbutazone (©)
Where V = mole of bound carbenoxolone per mole of protein 
A s molar concentration of free ligand
»° »Dialysis was carried out at ft C for 2*t hours with 
10 M bovine serum albumin in 0.1 M phosphate buffer 
at pH 7*^. Phenylbutazone was present in an equimolar ratio to
carbenoxolone.Resuits are the mean of 6 observations.
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Fig 2.3 VARIATION OF FLUORESCENCE INTENSITY WITH FLUORESCENT PROBE : 
CONCENTRATION, FOR BOVINE SERUM ALBUMIN.
Two ml of albumin solution, at 0.1 mg/ml (©) and 
l.Omg/ml (o), was titrated with l-anilino-8-naphthalene sulphonic acid 
(ANSA) at a concentration of 0.1 M in methanol. The fluorescence 
intensity was measured at 380/^70 nm.
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Fig 2.4 THE EFFECT OF DRUGS ON THE, FLUORESCENCE OF M S A  BINDING 
TO BOVINE SERUM ALBUMIN ' - .i’ _ ! ...
ANSA was titrated against 2 ml of bovine serum albumin, 
0.1 mg/ml in 0.05 M phosphate buffer at pH 7*4, alone (O)
~ -4 / Nand in the presence of 10 M  warfarin sodium (©), phenyl­
butazone (A), and carbenoxolone sodium (a).
Fluorescence v?as measured at 3^0/470 nm.
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Fig 2c5 SCATCHARD PLOT FOR THE BINDING QF ANSA TO BOVINE SERUM 
ALBUMIN IN THE PRESENCE OF VARIOUS DRUGS
Where V = mole of bound probe per mole of protein 
A = molar concentration of free probe
ANSA was titrated with bovine serum albumin in 0.05M 
phosphate buffer at pH 7.4 alone (O) and in the presence
-4 / %of 10 M warfarin sodium (©), phenylbutazone (A) and 
carbenoxolone (a ).
site. . The intercept o f .the abscissa was common for each 
plot, indicating binding at the same single class site.
The reduced slope in the presence of drugs is a result of 
the competition between the drugs and the fluorescent 
probe, being reduced almost equally for phenylbutazone and 
carbenoxolone, thus a similar affinity for each drug is suggested.
The affinity of warfarin for the site is less than the 
other drugs, indicating that this drug would be competitively 
displaced by both carbenoxolone and phenylbutazone. When 
ANSA was titrated in the presence of both warfarin and 
phenylbutazone there was no additive reduction in the 
fluorescence and this is interpreted as additional evidence 
that only one class of binding site was involved.
The binding of. carbenoxolone3 phenylbutazone and warfarin to 
human serum albumin. Titration of ANSA with 1.0 and 0.1 mg /ml 
human serum albumin gave similar results to those with bovine 
albumin. However, a higher level of fluorescence was seen 
with the human albumin than with bovine albumin (Fig. 2.6). The 
presence of the three drugs, carbenoxolone, phenylbutazone 
and warfarin resulted in a reduced fluorescence of the probe 
(Fig. 2.7) although the shape of the curve was not similar 
for all three drugs as was the case with bovine serum 
albumin (Fig. 2.4)
A Scatchard plot of the fluorescent probe binding to 
human serum albumin (Fig. 2.8) was non-linear but may be 
interpreted as representing three classes of binding site 
(n., = 1, nn = 3, nQ = 4). Carbenoxolone was bound at the
JL A o
first class of site whilst warfarin and phenylbutazone were'
bound at the second, where phenylbutazone had the higher
affinity. From these results it may be inferred that 
carbenoxolone would not compete with the other two drugs 
for a common binding site on human serum albumin, which is 
in contrast to the findings with bovine albumin. Both 
phenylbutazone and warfarin were bound at the same class of 
site on human albumin as was the case with bovine albumin. 
Phenylbutazone showed a higher affinity than warfarin in
0 2 4 6 8 10 12 14 16 18 20
ANSA concentration (xlO” M)
■ Fig 2,6 FLUORESCENCE INTENSITY OF ANSA WITH HUMAN
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AND BOVINE SERUM ALBUMIN
ANSA was titrated with 2ml human.(©) and bovine (a) 
albumin at 1.0 mg/ml in 0.05M phosphate buffer at 
Fluorescence was measured at 380/470 nm.
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Fig 2.7 THE EFFECT OF DRUGS ON THE FLUORESCENCE OF ANSA 
BINDING TO HUMAN SERUM ALBUMIN
ANSA was titrated with 2ml human serum albumin at 0.1 mg/ml 
in 0.05M phosphate buffer at pH alone (O) and in the
presence of 10~ M warfarin sodium (a ), phenylbutazone (A) 
and carbenoxolone (©). Fluorescence was measured at 3S0/470nm.
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Fig 2.8 SCATCHARD PLOT FOR THE BINDING OF ANSA TO HUMAN SERUM 
ALBUMIN IN THE PRESENCE OF VARIOUS DRUGS
Where V = mole of bound probe per mole of protein 
A a molar concentration of free probe
ANSA was titrated -with human serum albumin in 0.05^ 
phosphate buffer at pH 7« ^  * alone (O) and in the presence 
of 10*” M carbenoxolone (©), phenylbutazone (A) and
warfarin sodium (A) .
each case, leading to the suggestion that the competitive 
displacement of warfarin by phenylbutazone would occur.
2.3.3 ULTRAFILTRATION TECHNIQUE
The 'influence of ‘protein concentration. At the lower bovine
serum albumin concentrations carbenoxolone was present in a molar
excess and, in consequence, binding sites were saturated.
—5However, at the 1.0% albumin concentration 12.0 x 10 M carbenoxolone was
—5near maximally bound, whilst 52.8 x 10 M was only 61.8% 
bound, whereas the latter carbenoxolone level was maximally 
bound at a concentration of 10% albumin. It is interesting 
to note that at higher protein concentrations less binding 
of carbenoxolone to the visking dialysis sac was seen, as 
was the case with equilibrium dialysis.
Binding of carbenoxolone to bovine serum albumin. With bovine
-4serum albumin at a concentration of 10 M, maximal carbenoxolone binding 
was seen up to 250 ng/ml, when determination of the. free concentration 
was only just within measurable limits.
However, a Scatchard plot of the data (Fig. 2.9) was
linear, suggesting the presence of only one class of binding
-3site (n = 9) with an affinity of 8.1 x 10 1/mole. These 
results agree favourably with those obtained by equilibrium 
dialysis.
Binding of carbenoxolone to human serum albumin. Carbenoxolone 
< was bound to a slightly lesser extent to human serum albumin 
than to bovine albumin. At a concentration of 200 jig/ml only 92% was 
• bound to human albumin, whilst 97% was bound at 250 jig/ml to bovine albumin.
A Scatchard plot of the binding (Fig 2.10) was non­
linear suggesting (i) a significant electrostatic interaction 
between binding sites; (ii) the binding of carbenoxolone in 
different ionic states (it is a divalent ion); or more likely 
(iii) more than one class -of binding site exists in the 
albumin molecule. The primary binding site had a high
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Fig 2.9 SCATCHARD PLOT OF 3H~CARBENOXOLONE BINDING TO 
BOVINE SERUM ALBUMIN, FROM ULTRAFILTRATION STUDIES
Where V ^ mole of bound carbenoxolone per mole of* prot 
A t= molar concentration of free carbenoxolone
ein
Ultrafiltration was carried out at k C in 0.1 M  phosphate 
buffer at pH •
o
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Fig 2.10 SCAT CHARD PLOT OF '^H~CARBENOXOLONE BINDING TO 
HUMAN SERUM ALBUMIN, FROM ULTRA FILTRATION STUDIES
Where V = mole of bound carbenoxolone per mole of albumin 
A - molar concentration of free carbenoxolone
Ultra filtration v/as carried out at 4°C in 0,1 M phosphate 
buffer at pH 7.4 .
~ 3
-a-.-?
~ at least^10b l/mole 
' k2 = 7« 1 x 10’ l/mole
6affinity of at least 10 l/mole for carbenoxolone where
n1 = 3, whilst the second class of site had a lower affinity of 
37.1 x 10 l/mole where n^ ~ 7. The existence of more 
than one class of site is in contrast to the results with 
bovine albumin, but confirms the previous results in this 
chapter.
' The influence of phenylbutazone and warfarin on the binding of 
carbenoxolone to human albumin. At the lowest carbenoxolone 
concentration of 20 jug/ml, maximal binding was seen, * thus rendering 
measurements of the free drug difficult (Table 2.3), whilst 
at the higher level of-450/ig/ml, the level of binding was 
62%. The small changes induced by the presence of phenyl­
butazone and warfarin were within 12% of the original 
carbenoxolone levels suggesting that no real displacement 
had occurred.
TABLE 2.3 BINDING OF 3H-CARBENOXOLONE TO HUMAN SERUM
ALBUMIN BY ULTRAFILTRATION IN THE PRESENCE OF PHENYLBUTAZONE
Carbenoxolone Phenylbutazone Free concentration Degree of 
concentration concentration- (Af ■+ s . d . ) carbenoxolone
( jig/ml) ( fig/ml) ” binding (%)
20 - 0.8 x 10 1 + 0.17 99.7
20 100 1.0 x 10"7 + 0.10 99.6
450 - 28.5 x 10"5 + 3.2 62.1
450 225 32.3 x 10“5 + 2.4 58.3
Results are the means of 6 observations.
-4Ultrafiltration of 10 M human serum albumin in 0.1 M 
phosphate buffer at pH 7.4 was carried out at 4°C. 20 jig/ml
carbenoxolone represents therapeutic albumin/carbenoxolone 
levels and 100 pg/ml phenylbutazone is a 10-fold molar 
equivalent. 450 jig/ml carbenoxolone was a level approximate 
to 50% binding and 225 jig/ml of phenylbutazone is an 
equimolar level.
2.4 CONCLUSIONS
The present experiments with equilibrium dialysis have 
shown that the methodology is not entirely satisfactory for 
the evaluation for carbenoxolone binding. Significant 
binding of carbenoxolone to the visking membrane was 
encountered not only with equilibrium dialysis but also 
with ultrafiltration. Even though steps were taken to 
reduce the binding, it could not be abolished in the absence 
of protein, although it was further reduced in the presence 
of high concentrations of protein. Binding to membranes is 
a known impediment of these methods (Davison, 1971). Lindup 
(1971), using ultrafiltration techniques, did not encounter 
membrane.binding difficulties, although in the presence of 
whole serum the binding of carbenoxolone may be minimal.
The difficulties in obtaining equilibrium with carbenoxolone 
in the absence of protein may well be due to this extraneous 
binding.
Results from the equilibrium dialysis studies of 
carbenoxolone binding to bovine serum albumin showed that, 
in contrast to previous studies using human serum albumin, 
the drug was binding to one class of site only (Chakraborty, 
et al3 1970; Lindup, 1971; Parke & Lindup, 1973). These 
authors studied the protein binding of carbenoxolone in 
other species but only used whole serum rather than isolated 
serum protein. The present studies using a fluorescent 
probe have confirmed that there is only one single class of 
binding site for carbenoxolone on bovine serum albumin, 
although the actual number of binding sites per protein 
molecule are different according to the experimental method 
used. The present findings concerning the binding of 
phenylbutazone and warfarin to bovine serum albumin agree 
with those of Jun and colleagues (1972) so that the present 
results using a fluorescent probe are validated. A possible 
explanation for the difference found in the present work 
between equilibrium dialysis and . fluorescent probe 
methods may be due to differences in the ionic strength of 
the buffer used, since ionic strength did influence the
probe fluorescence and is known to alter protein binding 
(Davison, 1971). The buffer molarity was 0.1 M for 
equilibrium dialysis and ultrafiltration studies but 
0.05 M for the fluorescent probe method. Alternatively, the 
presence of binding sites on the visking membrane may 
constitute a second difference between these methods of 
measurement. Whatever small differences exist between the 
results obtained from the different methods, it is clear 
that only one class of binding site exists on bovine serum 
albumin for carbenoxolone, phenylbutazone and warfarin.
Thus the inference may be made that both carbenoxolone 
and phenylbutazone are likely to displace warfarin from 
binding sites on bovine albumin. In contrast, only 
phenylbutazone will displace warfarin from human albumin.
The latter interaction is well known from clinical and 
animal studies in vitro (Sigg, et ol3 1956; Aggeler, et al3 
1967; O'Reilly & Levy, 1970; Jun, et al9 1972). In 
addition, phenylbutazone has - been shown 
to displace carbenoxolone from bovine albumin binding 
sites. It is interesting to note that the presence of 
phenylbutazone reduces the number of binding sites for 
carbenoxolone from 9 to 6 which may, in part, be' the 
mechanism of displacement. In reducing the number of 
binding sites it is possible that phenylbutazone is (a) 
binding at 3 sites per molecule, thus reducing the number 
available to 6, or (b) inducing a conformational change in 
the albumin so that 3 carbenoxolone sites are no longer 
available, or (c). preventing a conformational change induced 
by carbenoxolone to increase the binding sites by 3. Parke 
and Lindup (1973) suggested that a conformational change was 
not likely to be induced by carbenoxolone on human serum 
albumin.
From the fluorescent probe study with bovine and human 
serum albumins, the results reveal a species difference.
With human serum albumin more than one class of binding site 
was present for the fluorescent probe itself. Carbenoxolone
was bound at the first class of site, whereas phenyl­
butazone and warfarin were bound at the second class of 
site, leading to the suggestion that carbenoxolone was 
not likely to interact with the other two drugs by 
competitive displacement.
Measurement of carbenoxolone binding by ultrafiltration
confirmed the species difference, and the Scatchard plot
of carbenoxolone binding was similar to that of Lindup
(1971) but with lower affinities. The present experiments
6suggest binding affinities of at least 10 l/mole and 
3
7.1 x 10 l/mole, for the two sites. Whilst Chakraborty
r 7 '  ( Z
and colleagues (1970) found 10 l/mole and 2 x 10 l/mole,
Parke and Lindup (1973) agreed with the former but interpreted ,
6the latter as 3 x 10 l/mole. The numbers of binding 
sites per molecule were also slightly different to previous 
workers, n^ = 3, and n^ = 7 in the present experiments, 
whilst previous results were n^ = 3, n2 = 6 (Chakraborty, 
et al3 1970) and n^ = 2, n2 = 4 (Parke & Lindup, 1973).
These differences may be due to slight changes in the 
methodology such as temperature, since it is known that 
protein binding may be temperature-dependant (Davison, 1971). 
The present experiments were performed at 4°C for comparison 
with the equilibrium dialysis. Lindup did not report the 
use of any de-fatting procedures for his crystalline albumin 
fractions, whilst in the present study such procedures did 
not alter the binding characteristics of the bovine or 
human serum albumin used. It is known that the presence of 
fatty acid contamination can cause alteration of binding 
characteristics (Chen, 1967). However, as most interpretations 
of binding data depend upon linear transformations and 
various constant assumptions, the method used to evaluate 
n and. k by different authors may influence the actual values 
obtained (Madsen & Robertson, 1974; Swillens & Dumont, 1975). 
Similar views on comparison between results of different 
•authors have been expressed by Vallner and colleagues (1976) 
who have illustrated the point by a literature survey of
dicoumarol binding affinity whose range showed a 30-fold 
difference between authors.
The present ultrafiltration studies also confirmed 
another prediction from the fluorescent probe study, in 
that phenylbutazone and warfarin were not seen to displace 
carbenoxolone from binding sites on human serum albumin 
either directly or by altering the available binding 
sites by conformational changes.
It is interesting to note that carbenoxolone, up to
a concentration of 250 jug/ml, was maximally bound to human
—4serum albumin at a concentration of 10 M. In whole 
blood this represents a binding capacity of carbenoxolone 
to albumin solution of 1.68 mg/ml, when assuming a serum 
albumin concentration of 4.5 g/dl. In turn this represents, 
for a blood volume of 5 litres and a dose level of 
carbenoxolone of 300 mg per day, a binding capacity for 
28 days accumulated dose. Therefore the capacity of 
albumin for the binding of carbenoxolone greatly exceeds 
the concentrations of carbenoxolone observed clinically.
Thus the present experiments in vitro have confirmed 
the high degree to which carbenoxolone sodium binds to 
albumin, maximal binding at therapeutic drug/albumin ratios 
being observed. A species difference in the binding of 
carbenoxolone and other drugs was clearly seen, suggesting 
that for extrapolation to the clinical situation, human 
serum albumin should be used. Some differences between 
experimental methods and authors were also indicated, 
suggesting that comparison between experiments in vitro 
should be carried out on one experimental model under 
identical conditions to enable suggestions for clinical 
interaction to be made. Studies along these lines are 
reported in Chapter 3.
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3.1 INTRODUCTION
Drug interactions are often complex in mechanism and 
cannot always be reliably predicted from studies in vitro. 
However, it is unrealistic to examine for all possible drug 
interactions in vivo (Modell, 1964). Investigation of 
the possible interactions of carbenoxolone, involving 
displacement from protein binding sites, followed careful 
selection of drug candidates. These included other protein- 
bound drugs which may be encountered in the clinical use 
of carbenoxolone, drugs which have shown 'classical' 
displacement interactions, representatives of drugs^ 
administered on a long-term basis and analogues of the drug, 
carbenoxolone, itself. The following introduction attempts 
to give the background to these drug candidates which- are 
listed in Table 3.1.
3.1.1 DRUG CANDIDATES FOR INTERACTION STUDY
Drugs which are detrimental to the gastro-intestinal tract
Carbenoxolone is a drug which heals gastric and duodenal 
ulcers and is therefore likely to be used concomitantly or 
after other drugs which may induce dyspepsia or ulceration, 
the most common of which are the non-steroidal anti-inflammatory 
agents. There are five main categories of non-steroidal 
anti-inflammatory agents, (i) salicylates, (ii) pyrazoles, 
(iii) anthranilic" acids, (iv) phenylalkanoic acids, and 
(v) indoleacetic acids.
The salicylates. In 1899 Dreser synthesised aspirin 
(Fig. 3.1) which is still the most extensively used 
analgesic-antipyretic and anti-inflammatory drug. In
Table 3.1 DRUG CANDIDATES FOR INTERACTION STUDY
IN VITRO WITH CARBENOXOLONE
1) Drugs detrimental to the gastro-intestinal tract
Non steroidal anti-inflammatory agents: 
aspirin
phenylbutazone 
flufenamic acid 
ibuprofen 
indomethacin
Corticosteroids:
prednisolone
2) Drugs which have, shown interaction by displacement from 
plasma binding sites
v/arfarin sodium
tolbutamide
chlorpropamide
3) Drugs employed in long-term therapy
phenytoin
imipramine
4) Analogues of carbenoxolone
enoxolone (parent triterpenoid)
cicloxolone (cyclohexane dicarboxylic acid 
replaces succinic acid)
common with other anti-inflammatory agents aspirin irritates 
the gastro-intestinal mucosa leading to haemorrhage and 
ulcer formation in man and animals (Paulus & Whitehouse, 
1973). It is readily absorbed from the stomach and is 
extensively bound to plasma proteins, mainly albumin, in 
the circulation (Goodman & Gilman, 1975b). Together with 
other salicylates, aspirin is known to displace many 
substances from plasma binding sites.
Pyrazoles. The pyrazoles as a class have been known for 
many years and were in use before the synthesis of aspirin, 
although phenylbutazone (Fig. 3.1) was introduced in 1949. 
Phenylbutazone is rapidly absorbed from the stomach and 
extensively bound to plasma proteins (Burns, et als 1953; 
1955). Its toxicity includes gastro-intestinal irritation 
(Steinberg, et al5 1953), although a significant portion of 
the drug’s potential toxicity lies in its ability to displace 
and potentiate many drugs from plasma binding sites 
(Goodman & Gilman, 1975b).
Anthranilic acids. The members of this group are the 
amine analogues of the salicylates, and include flufenamic 
acid (Fig 3.1). The analgesic potency of flufenamic acid 
is equal to that of the salicylates but the anti-inflammatory 
activity is less (Winder, et al3 1963; 1969). Flufenamic 
acid is rapidly absorbed from the stomach and is extensively 
bound to plasma proteins (Martindale, 1977). It is also 
known to displace and potentiate other drugs bound to plasma 
proteins (Goodman & Gilman, 1975b).
PhenylaVkanoic acids. This group of drugs was initiated 
with ibufenac and its methyl analogue, ibuprofen, 
which were synthesised in 1964 (Hart & Boardman, 1965). 
Ibuprofen (Fig. 3.1) possesses anti-inflammatory, antipyretic 
and analgesic activity but is less potent than aspirin 
(Adams,'et al3 1969a; 1969b). Oral doses are well absorbed 
and extensively bound to plasma proteins, being capable of
flufenamic acid
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CH-COOH
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indomethacin
Fig 3.1-N0N-STEH0IDAL AHTI-IHFLAMMATORY. AGEKTS
displacing other protein-bound drugs (Martindale, 1977). 
Gastro-intestinal irritation is considered to be less with 
ibuprofen than with aspirin but has produced peptic 
ulceration in combination with aspirin and exacerbated 
ulceration already present (Goodman & Gilman, 1975b).
Indoleacetic acids. This group was initiated in 1963 
with indomethacin (Fig. 3.1) which is a potent anti­
inflammatory and antipyretic agent, being more potent than 
aspirin (Winter, et al3 1963). Indomethacin is well absorbed 
from the gastro-intestinal tract and is about 90% bound 
to plasma albumin (Duggan, et al3 1972). Antagonism 
of its anti-inflammatory activity by aspirin has been
14
demonstrated with C-indomethacin both in animal models 
and clinically (Jeremy & Towson, 1970; Yesair^ et al3 1970), 
although these results were not confirmed with non-radioactive 
indomethacin (Champion, et al3 197-2). It is thought that the 
oral anticoagulants are not displaced by indomethacin 
-(Goodman & Gilman, 1975b), whereas sulphonamides are 
displaced and potentiated (Mclver, 1967). Indomethacin 
is irritant to the whole gastro-intestinal tract, not only 
leading to dyspepsia and peptic ulceration, but to ulcerative 
lesions of the bowel (Lovgren & Allender, 1965; Boardman 
& Hart, 1967; Duggan, et al3 1975). . These effects are 
readily demonstrable in small animals, especially following 
adrenalectomy (Thornton & Sacra, unpublished observations).
In common with the above anti-inflammatory agents, 
steroids with anti-inflammatory actions are also detrimental 
to the gastro-intestinal tract.
Corticosteroids3 both natural and synthetic, are used 
in many disorders ranging from replacement therapy, following 
adrenalectomy, to immunosuppression and anti-inflammatory 
therapy (Wilson & Schild, 1968). It is recognised that 
the side effects of corticosteroid therapy*are multiple 
and it has been suggested that they are enhanced b y .an
increase in free, plasma concentrations (Lewis, et aZ-^1971). 
Prednisolone (Fig. 3.2) was one of the early corticosteroids 
synthesised in 1959 and possesses glucocorticoid, immuno­
suppressive and anti-inflammatory actions. The drug is 
readily absorbed orally and is bound to plasma proteins 
only to the extent of about 55% (Lewis, et al3 1971). The 
same authors correlated increased prednisolone toxicity in 
elderly patients, with reduced plasma albumin levels and, 
presumably, reduced drug binding capacity.
Drugs which have shown displacement 'interactions
Cownarin anticoagulants. The oral anticoagulants are so 
called because, although they have no activity in vitro, 
they affect coagulation by competing with vitamin K during 
synthesis of prothrombin. One of the earliest recognised 
drug-drug interactions was that of phenylbutazone with 
oral anticoagulant agents (Sigg, et al3 1956) although the 
mechanism of displacement from plasma binding sites was 
not elucidated until later (Aggeler, et a'ls 1967; O ’Reilly 
& Levy, 1970). The coumarin anticoagulants, as a group, 
are subject to interaction changes of potency by several 
mechanisms, although displacement from plasma binding sites 
is a major one (Goodman & Gilman, 1975c). Furthermore, the 
plasma half-life of chlorpropamide, tolbutamide and 
phenytoin may be increased by concomitant therapy with 
coumarin anticoagulants (Koch Weser & Sellers, 1971).
Warfarin (Fig. 3.2) is the most widely used of the 
coumarin anticoagulants (Mackie & Douglas, 1978). The 
drug is readily absorbed from the gastro-intestinal tract 
and is highly bound to plasma proteins, with an average 
plasma half-life in man of 44 hours (Aggeler & O ’Reilly, 
1968). It is well known that several anti-inflammatory 
drugs will displace warfarin from plasma binding sites, 
and that warfarin, in turn, will, displace sulphonylurea 
hypoglycaemic agents (Stockley, 1974). Warfarin has thus 
become a ’classical' drug in the study.of drug interactions.
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3.2 DRUGS USED IN THE FLUORESCENT PROBE STUDY
Sulghonylurea oral hygoglycaemic agents. These agents 
stimulate the release of insulin from the.Islets of 
Langerhans in both man and-many animal species, but not 
in the dog (Root & Anderson, 1956). The synthesis of 
chlorpropamide (Fig. 3.2) in 1958 soon followed that of 
tolbutamide in 1956 (Fig. 3.2), these two agents being 
the most commonly used sulphonylureas..
Both tolbutamide and chlorpropamide are readily 
absorbed from the gastro-intestinal tract and are 
extensively bound to plasma proteins (Martindale, 1977; 
Crooks & Brown, 1974). The main difference in activity 
between these compounds lies in their different rates 
of metabolism. The plasma half-life of tolbutamide in 
man is about 5 hours, whilst that of chlorpropamide is 
about 36 hours (Goodman & Gilman, 1975a). Coumarin 
anticoagulant drugs, together with many other agents, 
will displace the sulphonylureas from plasma binding 
sites (Sise, 1967; Tannenbaum, et al> 1974; Brown & Crooks, 
1976).
Drugs used in long-term theragy
Dhenytoin (Fig. 3.2) was first introduced in 1938, 
(Merritt & Putnam, 1938a; 1938b) and is still one of the 
most widely used anticonvulsant drugs (Woodbury & Kemp, 
1971). It is a basic drug which has only a limited 
aqueous solubility and is thus slowly absorbed from an 
oral or parenteral dose (Glazko, 1972). The drug is 
70-95% bound to plasma proteins in circulation, with a 
half-life of about 24 hours in man, although the half-life 
is dose-dependant at high dose levels. The plasma half- 
life of phenytoin is decreased by concomitant therapy with 
other drugs, such as phenobarbitone, which induce hepatic 
microsomal enzymes. In contrast,. drugs such as disulfiram 
and dicoumarol will increase plasma levels of phenytoin by 
decreasing the metabolism.of the anticonvulsant (Reynolds, 
1967; Christensen & Skovsted, 1969). Displacement from plasma
binding sites has been demonstrated in vitro by tolbutamide 
and correlated with studies in vivo (Wesseling & Mols-Thurkow, 1975).
Imipramine (Fig. 3.2) is a basic drug belonging to the 
group of tricyclic antidepressant agents and was first 
evaluated as an antidepressant by Kuhn (1958). The drug 
is well absorbed from an oral dose and one of its 
metabolites, desmethylimipramine, is also pharmacologically 
active. The binding of imipramine to plasma proteins has 
been described as weak, whereas its.principal metabolites 
are more highly bound (Glassman & Perel, 1973; Glassman 
et alj 1973). The pharmacological activities of 
phenylbutazone and coumarin anticoagulants are potentiated 
by imipramine, due to an inhibition of liver microsomal 
enzymes, and hence the metabolism of the other drugs 
(Remmer & Mercker, 1965). A similar mechanism is thought 
to be the mode of the potentiation of phenytoin by 
imipramine (Borga, el al3 1969). However, the absorption 
of phenylbutazone is delayed by desmethylimipramine, 
possibly by its anticholinergic activity (Consolo, 1968).
Carbenoxolone analogues
Enoxolone (Fig. 3.3) is the parent triterpenoid of 
carbenoxolone, the hemi-succinate ester of enoxolone.
It has some anti-inflammatory activity similar to that of 
carbenoxolone, furthermore its metabolism and excretion 
are similar in the rat (Finney & Somers, 1958; Finney, et 
al> 1958; Parke, et al^  1963). Little study has been made 
of the protein binding of enoxolone.
Cieloxolone (Fig. 3.3) is the cyclohexane di-carboxylic 
acid analogue of carbenoxolone. This compound has a 
greater anti-inflammatory activity than carbenoxolone, 
with a similar effect on glycoprotein synthesis (Thornton, 
MacDonald, Sacra & Gottfried, unpublished observations).
The metabolism of cieloxolone is- also similar to that of 
carbenoxolone (Gilbert & Rhodes, personal communication).
enoxolone R
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Fig 3.3 AHAL0G11ES OF CARBENOXOLONE
3.1.2 PRESENT STUDIES
The binding of the fluorescent probes, l-anilino-8- 
naphthalene sulphonic acid (ANSA), to serum albumin was 
reviewed in the previous chapter. However, Jun and Luzzi 
(1971) have indicated that ANSA is probably binding to 
tryptophan residues on bovine serum albumin whilst a 
second experimental probe, N-benzyl-(5-dimethylamino- 
naphthalene)-l-sulphonamide (BANS), was more hydrophobic 
and therefore likely to bind at alternative sites. The 
fluorescent probe technique is a useful method of 
evaluating possible displacement interactions in vitro of 
carbenoxolone sodium. Studies with the second probe, BANS, are 
proposed here in addition to the use of ANSA.
The list of drugs to be used has been reviewed above. 
In an attempt to assist correlation with studies in vivos 
evaluation of the fluorescent probe binding to diluted 
whole serum is proposed, whereby the serum is diluted to 
the same albumin levels as that used in previous studies 
with crystalline albumins.
3.2 EXPERIMENTAL
3. 2.1 STUDIES OF THE BINDING OF CARBENOXOLONE AND OTHER DRUGS BY 
THE FLUORESCENT PROBE 'ANSA
The probe, l-anilino-8-naphthalene sulphonic acid
(ANSA), human serum albumin, buffer and solvents were used
as in the previous study (section 2.2.2). Carbenoxolone
sodium, cieloxolone, phenylbutazone, aspirin, imipramine,
prednisolone (all from Biorex Laboratories Ltd.), warfarin
(Gehardt-Penick), tolbutamide and chlorpropamide (both
from Berk Pharmaceuticals Ltd.), phenytoin sodium (Phase
Separations), flufenamic acid (Aldrich) and ibuprofen
(Boots Ltd.) were used as 0.1 M solutions in methanol.
Enoxolone (Biorex Laboratories Ltd.) and indomethacin
_2
(Merk, Sharpe & Dohme Ltd.) were used at 5 x 10 M and
-2cholesterol (BDH) at 2.5 x 10 M in methanol.
Fluorescence titrations and treatment of fluorescence 
data were performed as described previously (section 2.2.2).
Native fluorescence and interference with ANSA spectrum. Aliquots 
of 2 ml human albumin solution, with drug added, were placed 
in quartz cuvettes and scans taken to investigate native 
fluorescence around the specific wavelengths of the probe 
(380/470 nm). Excitation scans were taken from 310-420 nm 
and emission scans from 440-510 nm.
To investigate a possible shift in the excitation or
emission spectra of the probe, the latter^was added to the
-5drug-albumin complex at a level of 10 M and the 
excitation and emission scans repeated.
Samples of human serum albumin were subjected to the 
defatting technique of Chen (1967) and the fluorescence 
titrations repeated.
g. 2. 2 INVESTIGATION OF A SECOND FLUORESCENT PROBE (BANS)
W-Se«t2-£l
BANS y[5-dimethylaminoaphthalene]-1-sulphonamide) 
was synthesised by reacting dansyl chloride with excess 
benzylamine (Fig. 3.4).
Binding studies. The probe, BANS, was used as a 10 M
solution in methanol. Protein and drug solutions were as ■
in the ANSA study above (section 3.2.1) and the fluorescence
titrations performed as with ANSA. Fluorescence scans of
the excitation and emission wavelengths were carried out
with BANS in 0.05 M phosphate buffer at pH 7.4. Scans were
taken of the free probe and when bound to human serum
albumin at a concentration of 1.0 mg/ml. The effect on the
fluorescence spectrum of the displacement of the probe,
-4by phenylbutazone at a concentration of 10 M, was also 
investigated.
3.2.3 FLUORESCENCE STUDIES WITH DILUTED RAT AND HUMAN SERA
Attempts were made to correlate the fluorescence 
titrations of albumin fractions with those of whole serum 
diluted to produce the same albumin concentrations (0,1 and 
1.0 mg/ml). Human and rat sera were used.
Serum albumin assay. This manual method is based on the 
automated assay in use in Biorex Laboratories using 
bromocresol green binding (Technical Bulletin No. 11, October 
1967. Association of Clinical Biochemists Scientific 
Technical Committee). Citrate buffer (lAf) was used at pH 3.8 
whilst the colour'reagent stock solution contained bromocresol 
green and 0.1 M NaOII. An EEL Colorimeter (Spectra 197) was 
used with measurements made at 635 nm. Blanks were used 
with citrate buffer and serum whilst 10 p. 1 of serum in 2 ml 
bromocresol green reagent was assayed. The reagent quantitatively 
developed a blue colour when protein-bound, the absorption
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of which was measured at 635 nm. Crystalline human serum 
albumin was used for calibration and a standard serum,
'Monitrol1, included to verify the assay.
Fluorescence titrations. Human blood was collected from 
two male volunteers, placed in a polypropylene tube and 
allowed to clot at 4°C for 30 minutes. The serum was 
collected, after centrifugation, and stored at -20°C until 
used.' Rat serum was.prepared in a similar way but collected 
from the abdominal aorta under ether anaesthesia from 
350 g male Biorex Wistar rats. The serum was assayed 
for albumin content, then diluted with 0.05 M phosphate
buffer at pH 7.4 to give 0.1 and 1.0 mg/ml solutions of albumin. The 
diluted sera were titrated with the probe ANSA in the same 
way as for the crystalline albumin fractions (section 3.2.1)
3.3 RESULTS
3.3.1 THE BINDING OF CARBENOXOLONE AND OTHER DRUGS BY THE FLUORESCENT 
PROBE ANSA
Titration of the fluorescent probe, ANSA, with human 
serum albumin at a concentration of 0.1 mg/ml demonstrated 
a saturation of binding sites, but at 1.0 mg/ml a linear 
increase in fluorescence with probe concentration was evident 
(Fig. 3.5). The Scatchard plot of the probe binding was non­
linear, suggesting the presence of 3 classes of binding sites 
on human serum albumin (Fig. 3.6) where n^ = 1 ,  n^ = 3, 
n^ = 4, being confirmed by regression analysis of the 3 
linear portions (coefficients 0.93, 0.99 & 0.96).
The presence of various drugs reduced the fluorescence 
by competitive displacement of the probe. With the present 
series of drugs, binding was clearly differentiated into 
three groups:
i) The group which exhibited binding at the class I binding 
site only (n = 1) comprise the first category, group 1 (Fig.
3.7). The group includes carbenoxolone, enoxolone, 
cieloxolone, indomethacin and cholesterol.
ii) Those drugs which were bound to the class II site 
only (n = 3) comprise the second category, group 2 (Fig.
3.8). The group includes flufenamic acid, phenylbutazone, 
warfarin, tolbutamide and imipramine.
iii) Those drugs which displayed binding with a weak 
affinity to both class I and class II sites comprise group 3 
(Fig. 3.9) and include phenytoin, prednisolone, aspirin, 
chlorpropamide and ibuprofen.
llative fluorescence and interference with the ANSA spectrum.
None of the above drugs showed any interference with the 
fluorescence spectrum of the probe, except by reducing the 
fluorescence intensity. Native fluorescence was absent in 
most of the drugs with the following exceptions: flufenamic 
acid fluoresced in ethanolic solution with Xactivation 
400 nm and X fluorescence 475 nm. This fluorescence 
underwent a change when bound to human albumin, becoming
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Fig 3.5 VARIATION OF .FLUORESCENCE INTENSITY WITH FLUORESCENT 
PROBE CONCENTRATION, FOR HUMAN SERUM ALBUMIN .
Two ml of albumin solution,at O.lmg/ml (©) and 
l.Omg/ml (o), was titrated with l-anilino-8-naphthalene sulphonic 
acid (ANSA)at a concentration of 0.1 14 in methanol. The fluorescence 
intensity was measured at 380/^ 70 run.
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Fig 3.6 SCATCHAKD PLOT FOR ANSA WITH HUMAN SERUM ALBUMIN
Where V is the mole ratio of bound ligand per mole of albumin 
and A is the molar concentration of free ligand.
Two ml of human serum albumin solution,at concentrations of 1.0 
and O.lmg/ml in O.OfjM phosphate buffer at pH7.4 , were titrated with 
l-anilino-8"naphthalene sulphonic acid (ANSA) at a concentration of 
O.lM in methanol.
The.abscissa intercepts reveal three classes of binding site, 
n-pl, n?=3, iiyk .
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Fig 3.7 SCATCHARD PLOT FOR DRUGS BINDING TO HUMAN. ALBUMIN
Where V is the mole of bound ligand per mole of albumin and 
A is .the molar concentration of free ligand.
Results are from the titration of the probe, ANSA, vrith human 
serum albumin in 0.05M phosphate buffer at pH in the presence of 
the follovdng drugs at 10 Si; carbenoxolone (e) , cicloxolone (O), 
indomethacin (A), enoxolone (©)and cholesterol(a )' .
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Pig 3.8 SCATCHARD PLOT FOR DRUGS BINDING TO HUMAN ALBUMIN
Where V is the mole of bound ligand per mole of albumin and 
A is the molar concentration of free ligand.
Results are from the titration of the probe, ANSA, with human 
.serum albumin in 0.05M phosphate buffer at pH 7A  in the presence of 
the following drugs at lO^Mj flufenamic acid (ej), phenylbutazone (o), 
warfarin (a), tolbutamide (©) and imipramine (a).
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Fig; 3.9 SCATCHAKD PLOT FOR THE BINDING OF DRUGS TO HUMAN ALBUMIN 
Where V is the mole of bound ligand per mole of albumin and 
A is the molar concentration of free ligand.
Results are from the titration of the probe, ANSA, with human 
serum albumin in 0.03>M phosphate buffer at pH in the presence of
the following drugs at 10 ; prednisolone (o), aspirin (a) ,
ibuprofen (□)» chlorpropamide (©) and phenytoin (a ) .
350 and 440 nm respectively. However, this native 
fluorescence was negligible and did not interfere with 
that of the bound probe at the respective activation and 
fluorescence wavelengths of 380 and 470 nm. Similarly 
warfarin in ethanolic solution demonstrated native 
fluorescence at 360/400 nm which changed to.320/440 nm when 
bound to human albumin. This did not interfere with the 
probe fluorescence. Imipra.mine demonstrated two episodes 
of native fluorescence when bound to human serum albumin 
at wavelengths of 380/430nm and 410/470 nm, although again 
this fluorescence was negligible at 380/470 nm.
Defatting of human albumin. Following defatting of the 
human serum albumin by the method of Chen (1967), no changes 
in the fluorescence of the probe ANSA, or the Scatchard 
plot of binding, were seen (Fig. 3.10). This finding 
confirmed that the sample of albumin used was of sufficient 
quality not to require further purification.
3.3.2 STUDIES WITH A SECOND FLUORESCENT PROBE (BANS)
The purity of BANS was evaluated by an infra-red scan 
of a nujol mull preparation yielding absorptions in the 
appropriate regions corresponding to the desired structure. 
The melting point was 141-142°C.
Binding studies
Fluorescence spectrum. A scan of the fluorescence of BANS in
methanolic solution revealed a native fluorescence at
385/520 nm which was also present, although weak, in a
solution of buffer at pH 7.4 (Table 3.2). However, when
bound to human serum albumin the fluorescence was some 30
times higher and underwent a blue shift to 350/480nm.
Addition of phenylbutazone to give a concentration of 
-4
10 M reduced the fluorescence to zero but caused the 
reappearance of the fluorescence at 385/540 nm. This 
suggested that BANS had been displaced from the albumin by 
phenylbutazone.
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Fig 3.10 COMPARISON OF THE FLUORESCENCE OF NORMAL AND DE-FATTED
HUMAN ALBUMIN, WITH'THE FLUORESCENT PROBE ANSA
Two ml of albumin solution, normal (O) and de-fatted by the 
method of Chen (19&7) (©);» at 1,0 mg/ml were titrated with the fluorescent 
probe l-anilino-8-naphthalene sulphonic acid (ANSA) a.t a concentration 
of 0.1 M in methanol. The fluorescence was measured at 330/470 nm.
Fluorescence titration. The fluorescence of BANS,
when bound to human serum albumin, was much lower than
that for ANSA, and was reduced .in the presence of
warfarin and phenylbutazone, both at a concentration 
-4of 10 M. In contrast, the presence of carbenoxolone 
did not displace the probe. However, the Scatchard 
plot of binding was parallel to the abscissa perhaps 
indicating a non-specific binding.
3.3.3 FLUORESCENCE STUDIES WITH DILUTED RAT AND HUMAN SERA
Albumin assay. Standards of human serum albumin 
gave a curvilinear plot but were consistently reproducible 
and in agreement with the 'Monitrol’ Standard.
Fluorescence titrations. Titrations of both diluted 
rat and human serum produced a fluorescence which was 
similar to that of the crystalline albumin fractions. 
However, there was a slight tailing off of fluorescence 
at an albumin concentration of 1.0 mg/ml. A Scatchard 
plot of the binding of both rat and human serum revealed 
only one class of binding site for ANSA (n = 1) (Fig.
3.11). The presence of displacing drugs caused only 
minimal reduction cf fluorescence and did not significantly 
alter the Scatchard plot.
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Fig 3.11 SCATCHARD PLOT FOR ANSA WITH DILUTED RAT AND HUMAN SERUM
Where V is the mole ratio of bound ligand per mole of albumin 
and A is the molar concentration of free ligand.
Two ml of rat (a) and human (O) sera, diluted to 0.1 and 1.0 mg/ml 
albumin concentration in 0.05M phosphate buffer at pH 7»^ > were 
titrated with l-anilino-8-naphthalene sulphonic acid at a concentration 
of . 0.1M in methanol.
3.4 CONCLUSIONS
The fluorescent probe technique is an indirect 
assessment of protein binding but gives a good 
qualitative correlation between the protein binding 
affinities of the drugs used.
The results of this study allow the 
arrangement of the drugs into three 
groups, and the prediction of drug-drug displacement
interactions (Table 3.3). From group 2 it may be inferred 
that phenylbutazone would displace warfarin and both, in 
turn, would displace tolbutamide; indeed, such interactions 
have been demonstrated in vivo (Aggeler, et al3 1967; 
O'Reilly & Levy, 1970; Assandri & Perazzi, 1976). Within 
group 1 it is possible to suggest that carbenoxolone 
would displace not only indomethacin but its own analogues 
and cholesterol. Interaction between these drugs from 
groups 1 and 2 is not considered likely because the drugs
are binding at differing classes of site. This suggestion
has been inferred elsewhere, in that indomethacin is 
thought not to potentiate the coumarin anticoagulants 
(Goodman & Gilman, 1975b).
The drugs from group 3 were bound at the class
I and II sites but with a weaker affinity than those drugs
which were bound to only one of the sites. .These findings lead to 
the prediction of possible displacement by drugs from both 
group 1 and group 2 of those in group 3. Again, some of 
these displacement interactions have been demonstrated 
both in vivo and in vitro . Indomethacin is known to displace 
aspirin from one of its two binding sites in vitro, although 
the reverse effect is seen tn vivo, with the possible 
explanation being due to the prevention of indomethacin 
binding at its primary site by the presence of aspirin at 
the secondary site (Mason & McQueen, 1974). Furthermore, 
both phenylbutazone and warfarin.are known to displace 
tolbutamide (group 2) and chlorpropamide (group 3) 
(Stockley, 1974; Assandri & Perazzi, 1976).
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Thus from the various known interactions between the 
drugs included in this study, there is good evidence to 
suggest that interpretation of drug displacement inter­
actions from this model are valid. However, as was 
demonstrated with indomethacin and aspirin, in vitro drug 
interactions are not always in accordance with the 
situation in vivo (Mason & McQueen, 1974).
Further attempts to validate this fluorescent probe 
technique with ANSA were carried out with the second 
probe BANS, which is a more hydrophobic molecule. However, 
the usefulness of BANS, under the conditions used, did not 
merit its suggested, role by other workers 
(Jun & Luzzi, 1971). The exact conditions used by these 
authors were not stated, but were possibly different to 
those used in the present series, in that a variation of 
the pH or buffer ionic strength may be necessary for the 
use of this probe. The pH of 7.4 was chosen in the present 
experiments as the average blood pH in order to obtain the 
closest possible correlation in vitro with normal conditions 
in vivo. It is also pertinent to note that the original 
authors used bovine and not human serum albumin as in the 
present experiments; even so, satisfactory results were 
not obtained in the present study using, bovine serum albumin.
Fluorescence titrations of ANSA with diluted huma.n 
serum revealed only one class of binding site and thus did 
not correlate with the studies usings a crystalline albumin 
fraction. There are several reasons why the binding of 
the fluorescent probe may be different for the two protein 
preparations. The preparation and reconstitution of Cohn 
fraction V albumin may alter the secondary protein 
configurations and, in consequence, the binding sites, 
because even such small changes as the ionic strength of 
buffer will alter the binding characteristics of protein 
(Davison, 1971). A further complication may arise in the 
assay of the albumin portion of serum9in that the number 
of binding sites per molecule for bromocresoT green may
differ slightly from those for the fluorescent probe 
ANSA. If an excess of albumin were present then only 
the primary, high affinity, site would be occupied, 
accounting for the single class of binding seen with 
diluted human and rat sera. A more likely explanation 
is that the presence of free fatty acids, or cholesterol, 
in the diluted sera prevented the fluorescent probe from 
binding to the secondary and subsequent sites. The 
presence of other proteins such as globulin may also be 
considered to alter the binding pattern of the probe.
In conclusion from these findings in vitro it is 
possible to postulate that carbenoxolone will not displace 
such drugs as warfarin and tolbutamide from their plasma 
binding sites in vivo. However, it is also obvious that 
any study in vitro cannot adequately reproduce the 
conditions encountered in vivo. Even the study in vitro 
with dilute serum did not correlate with the use of 
albumin fractions. Therefore, in order to obtain 
confirmation of these predictions from studies in vitro3 
further studies in vivo should be carried out. Such 
studies are presented in the following chapter.
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DRUG INTERACTIONS OF CARBENOXOLONE IN VIVO
4.1 INTRODUCTION
To assess the effect of carbenoxolone on the displacement 
of drugs from plasma binding sites -m vivos drugs with 
readily detectable pharmacological activities were selected 
from each of the representative groups of binding patterns 
discussed in the previous chapter. The selected drugs 
were warfarin, tolbutamide, chlorpropamide and phenytoin.
The pharmacological activities of these drugs were monitored 
initially alone, then in the presence of a known displacing 
agent, phenylbutazone, and finally in the presence of 
carbenoxolone. The binding activities and pharmacological 
actions of the selected drugs are summarised below, together 
with the rationale of the methodology for estimation of 
their pharmacological potency.
Warfarin is bound to human serum albumin at a single 
class of site, identical to that of phenylbutazone but 
different to that of carbenoxolone. Phenylbutazone is known 
to displace warfarin from plasma binding sites, thus 
increasing the free concentration and potentiating the 
pharmacological activity of warfarin (O’Reilly & Levy, 1970). 
Warfarin exerts its mode of action because of its structural 
similarity to vitamin K, with which it competes during the 
synthesis of prothrombin (O’Reilly & Aggeler, 1968) and 
also reduces the extrinsic Factors VII and X. Prothrombin, 
or Factor II, forms part of the final stages of both the 
extrinsic and intrinsic pathways of coagulation at the 
stage of thrombin formation in the presence of Factor V and 
calcium ions (Simmons, 1968). Prothrombin times measure 
Factors II, V, VII and X and are thus an adequate estimation 
of warfarin activity.
Tolbutamide .Is bound to human serum albumin 
in a similar manner to warfarin, and is also potentiated by 
phenylbutazone (Assandri &.Pera.zzi, 1976). The pharmacological 
action of this sulphonylurea is believed to be due to the 
stimulation of insulin release from the pancreas (Root & 
Anderson, 1956). Measurement of blood glucose levels in 
glucose-loaded rats will estimate the pharmacological 
potency of tolbutamide (Loubatieres, 1964).
Chlorpropamide, in contrast to tolbutamide, is 
bound to human serum albumin at two classes of site, 
namely those of carbenoxolone and of phenylbutazone. As 
its pharmacological action is similar to that of tolbutamide, 
measurement of blood glucose levels in glucose-loaded rats 
will give an assessment of chlorpropamide activity.
Phenytoin -is ,bound to • human serum albumin 
in a similar manner to chlorpropamide and is also displaced 
from binding sites by phenylbutazone in vivo (Borga, et al3 
1969; Lunde, et al} 1970). Although its mode of action is 
unclear, the pharmacological activity of phenytoin may be 
measured by the inhibition of electroshock-induced convulsion 
(Toman, et al3 1946).
Phenylbutazone is bound to human serum albumin at the 
same sites as warfarin and tolbutamide, and shares one 
of the two binding sites of chlorpropamide and phenytoin. 
Phenylbutazone is known to displace and pptentiate the 
pharmacological activities of the preceeding drugs and is 
included in the present study to validate the experimental 
models.
4.2 : EXPERIMENTAL
Dose levels expressed as mg/kg refer to mg/kg body 
weight throughout this and subsequent chapters.
4.2.1 WARFARIN-CARBENOXOLONE INTERACTION
This interaction was assessed by monitoring the 
effect on warfarin-prolonged prothrombin times.
Prothrombin estimations. These were carried out using 
the method of Quick (1935) with modifications introduced 
by Simmons (1968). Blood samples were obtained, under 
ether anaesthesia, using citrate/hepes buffer (0.13 M 
trisodium citrate and 0.05 M N-2-hydroxyethylpiperazine-N-2 
ethanesulphonic acid) as anticoagulant (0.1 ml per ml of 
collected blood). Plasma was obtained by centrifugation 
at 1,150 g in an MSE bench centrifuge. Ereeze-dried 
rabbit brain thromboplastin was used (Diagnostic Reagents 
Ltd.) and reconstituted prior to use.
Pyrex tubes (0.4 cm x 4 cm) were placed in a water 
bath at 37°C and aliquots of thromboplastin (0.1 ml) 
and plasma (0.1 ml) were added to each tube. Prewarmed 
0.025 M aqueous calcium chloride (0.1 ml) was then added 
to each tube and a stop-watch was started immediately.
The time taken for the appearance of a fibrous clot was 
.recorded. Estimations of clotting times were performed in 
duplicate and, if the difference between the duplicated 
times was greater than 0.5s, a second duplicate estimation 
was carried out.
The effect of warfarin, carbenoxolone and phenylbutazone on 
prothrombin times. Groups of 8 female Biorex Wistar rats 
(200+ lOg body weight) were fasted for 16 hours prior 
to treatment and were fed 8 hours after treatment. Warfarin 
was administered, by intubation, as an aqueous solution in 
a volume of 5ml/kg. A dose-response study of warfarin was 
carried out using dose levels between 1 and 20 mg/kg, after
which a single, dose of. 10 mg/kg was used, for subsequent 
studies; Phenylbutazone and carbenoxolone were administered, 
subcutaneously in 0.9% NaCl (5ml/kg) at dose levels of 
20 and 40 mg/kg respectively (twice the molar equivalent of 
warfarin).to assess any inherent activity on prothrombin 
times. Measurements of prothrombin times were made 1, 2,
4, 6, 8 and 24 hours after treatment. ,
A second series of tests was carried out with concomitant 
administration of either phenylbutazone or carbenoxolone 
with the warfarin.
4.2.2 TOLBUTAMIDE-CARBENOXOLONE INTERACTION
This interaction was assessed by monitoring the drug- 
induced fall of blood glucose concentrations in hyperglycaemic 
rats. Measurements of whole blood glucose concentrations 
were performed by the glucose oxidase method of Trinder 
(1969a, 1969b) using a Technicon Autoanalyser II.
Groups of 8 female Biorex Wistar rats (200 + lOg body 
weight) were fasted for 16 hours prior to being 
rendered hyperglycaemic by the method of Sacra and 
Adamkiewicz (1965), which uses an oral load of 6 m mol 
glucose/lOOg body weight administered as a 3M solution. All drug 
treatments were given orally in 0.01% aqueous Tween 80 solution at a 
volume of 5ml/kg. A dose-response study of tolbutamide was carried out using 
dose levels between 50 and 200 mg/kg, a,fter which a level 
of 50 mg/kg was used for subsequent studios.
Two models of interaction were studied, the first in which 
the interacting drug (phenylbutazone or carbenoxolone) was 
given before the tolbutamide, and the second in which the 
interacting drug was given in divided doses both before and 
after the tolbutamide (Table 4.1).
In the first model of interaction, tolbutamide was 
given alone 1 hour after the glucose load. Phenylbutazone 
or carbenoxolone were given 30 minutes after the glucose
Table 4.1 SCHEDULE.OF TREATMENTS DURING 
SULPHONYLUEEA-DRUG INTERACTION STUDIES
Time (h) Model 1 Model 2
0 Glucose load
j
Interacting drug 
(equimolar)
12 Interacting drug 
(twice molar)
Sulphonylurea
1 Sulphonylurea
T
Glucose load
2 Blood sample
4
Interacting drug 
(equimolar)
' — ~
r
Blood sample
4 Blood sample
1
4 h — - L Blood sample
6 Blood sample
1
---
6i ---
L
Blood sample
All treatments were oral. In Model 1 the interacting drug, 
carbenoxolone or phenylbutazone, was given at a dose level 
twice the molar equivalent of tolbutamide or chlorpropamide. 
In Model 2 this dose was divided into two equal portions.
load, at dose levels of 114 and 227 mg/kg (twice the molecular equivalent 
of tolbutamide). Blood samples were taken 2, 4 and 6 hours 
after the glucose administration. This regimen was repeated 
for carbenoxolone with bilaterally adrenalectomised rats,
21 days post-operatively. At termination the rats were 
examined to verify complete adrenalectomy.
The second model of interaction involved the treatments 
with phenylbutazone, or carbenoxolone, being given in two 
equimolar portions 1 hour before the glucose load and 1 hour 
after. Tolbutamide was administered 30 minutes before
the glucose load and blood samples taken 1|, 3-|, and 5-1 hours 
after the load.
4. 2, 3 CHL0RPR0PAMIDE-CARBEN0X0L0NE INTERACTION
This interaction was assessed by the second model above 
(section 4.2.2) in which the interacting drugs, phenylbutazone 
and carbenoxolone, were given in two administrations of 
56 and 111 mg/kg respectively (the molar equivalents of 
chlorpropamide). Chlorpropamide was administered at 50 mg/kg.
4.2.4 PHENYT0IN-CARBEN0X0L0NE INTERACTION
Interaction with phenytoin was assessed by measurement 
of the effect on the protection of phenytoin against 
(electroshock-induced convulsion.
Electro-shock convulsion was induced by the method of 
Toman and colleagues (1946). Two electrodes were placed 
sub-cutaneously, just posterior to the ears, to deliver 
pulses at a rate of 100 per second for a duration of 1 second 
at 80 volts and 200 mA. The pulse width was 5msec. A dose-response 
study of phenytoin was carried out, between 30 and 100 mg/kg, to establish 
an ED.cn, the level required to inhibit tonic seizure in 50%DU
of the rats. The effect of concomitant doses of phenylbutazone 
(100 mg/kg) and carbenoxolone (200 mg/kg) with phenytoin 
(39 mg/kg) was then investigated. Dose levels of
phenylbutazone and carbenoxolone were twice the molar
equivalent of phenytoin. Phenylbutazone and. carbenoxolone 
were evaluated, at 200 and 400 mg/kg respectively, for 
intrinsic activity on electroshock-induced convulsions.
4.3 RESULTS
4.3.1 WARFARIN-CARBENOXOLONE INTERACTION
Treatment of rats for two days with warfarin, at a 
dose level of 4 mg/kg, produced a ten-fold increase in 
prothrombin time 48 hours after treatment. No effects 
of warfarin treatment were observed on the prothrombin 
time within an 8 hour period following treatment. At a 
dose level of 10 mg/kg, warfarin caused an increase in 
prothrombin time of nearly five-fold (p< 0.001) 24 hours 
after treatment (Table 4.2). Maximal increases in 
prothrombin times were seen with dose levels greater than 
20 mg/kg. Phenylbutazone and carbenoxolone were without 
inherent- activity on prothrombin times, at the dose levels 
used (Table 4.2).
Phenylbutazone showed a significant (p< 0.005) 
potentiation of warfarin activity, by causing an increase 
in the prothrombin time from 73.2 to 109.7 s. In contrast, 
the co-administration of carbenoxolone did not alter the 
prothrombin time from that following treatment with 
warfarin alone.
The inference from these findings must be that 
carbenoxolone does not displace warfarin from plasma 
binding sites leading to potentiation of its pharmacological 
activity, as is the case with phenylbutazone.
4.3.2 TOLBUTAMIDE-CARBENOXOLONE INTERACTION
Treatment with tolbutamide, at a dose level of 50 mg/kg, 
produced a significant reduction in blood glucose 
concentrations 2 and 4 hours after the glucose load. The 
reduction was not maximal, but this dose level was chosen 
to enable both potentiation and inhibition to be detected.
Phenylbutazone was without intrinsic activity on blood 
glucose concentrations (Table 4.3) but did significantly
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potentiate the tolbutamide response at 2 and 4 hours 
(p<0.05) after the glucose load. This potentiation 
confirms the findings in vitro and clinically of other 
workers (Brown & Crooks, 1976; Tannenbaum, et al> 1974) 
and validates the model system.
Treatment with carbenoxolone, at a dose level of 
227 mg/kg, reduced blood glucose concentrations at 4 
hours by 7% with respect to controls (Table 4.4) which, 
due to the small spread of results, was just a significant 
difference (p< 0.05). However, at 6 hours the glucose 
concentration in the carbenoxolone group was 6% higher 
than controls (p >0.05), and w a s 'reflected in the group 
receiving both tolbutamide and carbenoxolone, where the 
glucose concentration was significantly higher than in 
the group which received only tolbutamide (p<0.01).
There was also an elevation in blood glucose concentrations 
(14%, p>0.05) at the 2-hour stage following combined 
treatment with carbenoxolone and tolbutamide. Despite 
these changes carbenoxolone did not potentiate the 
activity of tolbutamide at 2 or 4 hours after the glucose 
load, as was the case with phenylbutazone treatment.
Because of the elevation of blood glucose concentration 
following concomitant therapy with tolbutamide and carben­
oxolone, the treatment was repeated in adrenalectomised 
rats. The responses to the glucose load and tolbutamide 
treatments were not greatly altered by adrenalectomy 
(Fig. 4.1). Treatment with carbenoxolone did not alter 
either the normal blood glucose concentration or the 
response to tolbutamide in adrenalectomised rats (Fig. 4.2).
In the second series of tests, when phenylbutazone 
and carbenoxolone were given both before and after the 
glucose load phenylbutazone significantly potentiated the effect
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Fig 4.1 BLOOD GLUCOSE CONCENTRATION -IN NORMAL AND ADRENALECTOMISED
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FEMALE RATS, FOLLOWING AN ORAL GLUCOSE LOAD
The rats were fasted for 16 hours and given an oral glucose load 
of 6 mmol/lOOg (as a 2>'A solution) followed 1 hour later by tolbutamide 
treatment (t) at an oral dose level of 50ms/kg«,The adrenalectomised rats 
were used 21 days post-operatively. The groups were ; normal rats, 
control(o) and tolbutamide-treated (a) ; adrenalectomised rats, 
control (©) and tolbutamide-treated (a) .
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Fig 4.2 CONCENTRATION OF BLOOD GLUCOSE IN ADRENALECTOMISED RATS
FOLLOWING AN ORAL GLUCOSE LOAD AND TREATMENT WITH TOLBUTAMIDE
The rats were fasted for 16 hours and given an oral glucose 
load of 6 mmol/lOOg (as a 3H solution). Controls (o) received vehicle 
only, carbenoxolone (©) was given 30 win. after the load (a) and 
tolbutamide ([l) 1 hour after the load (b)« Combined treatment (□) was 
given at the sane time intervals. Tolbutamide was given at a dose level 
of 50 mg/kg and carbenoxolone at 227 mg/kg, twice the molar equivalent 
of tolbutamide.
of tolbutamide (Table: 4.5) thus validating this model. 
Carbenoxolone treatment at a dose level of 227 mg/kg 
(Table 4.6) again resulted in elevated blood glucose levels 
which were significantly higher than controls at 6£- hours 
(p<0.05). Furthermore, the response to tolbutamide was 
reduced by carbenoxolone at hours (p <0.05) although 
no changes were seen at the earlier stages.
4.3.3 CHL0RPR0PAMIDE-CARBEN0X0L0NE INTERACTION
Concomitant administration of phenylbutazone and 
chlorpropamide (Table 4.7) resulted in a greater potentiation 
than was seen with phenylbutazone and tolbutamide. Treatment 
with carbenoxolone again resulted in glucose levels which 
were slightly higher than controls (Table 4.8). However, no 
change in the activity of chlorpropamide was evident.
The inference from these findings is that carbenoxolone 
is not displacing either tolbutamide or chlorpropamide from 
plasma binding sites, leading to potentiation, as is the 
case with phenylbutazone. The apparent inhibition of 
tolbutamide activity by carbenoxolone is likely to be due 
to an intrinsic activity of carbenoxolone rather than a 
direct effect upon tolbutamide itself.
4.3.4 PHENYT0IN-CARBENOXOLONE INTERACTION
Phenytoin inhibited the electroshock seizure 
by 50% at a dose level of 39 mg/kg when administered 2 hours 
prior to the shock. Neither phenylbutazone at 200 mg/kg 
nor carbenoxolone at 400 mg/kg induced any cha.nge in the 
electroshock response (Table 4.9).
Concomitant treatment with phenylbutazone at a dose level of twice the 
molar equivalent of the of phenytoin did not cause a
significant change in the protection of the anticonvulsant 
(Table 4.10). Although phenylbutazone is known to displace 
phenytoin from plasma binding sites in vitro, an aJteration of
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the pharmacological potency of phenytoin by this mechanism 
has not been demonstrated in vivo. However, an increase in 
the clinical side-effects of phenytoin by concomitant 
therapy with chlorpheniramine has been attributed to 
displacement from plasma binding sites (Pugh, et aly 1975). 
Similarly, carbenoxolone did not alter the effect of 
phenytoin.
4.4 CONCLUSIONS
The potentiation of the pharmacological activities of 
warfarin, tolbutamide ana chlorpropamide by concomitant 
administration of phenylbutazone was clearly demonstrated, 
confirming the various animal and clinical findings and 
the predictions from the previous studies in vitro. The 
mode of action of the potentiation has been elucidated as 
displacement from plasma binding sites for warfarin but 
has only been suggested for the sulphonylureas (O’Reilly 
& Levy, 1970; Slade & Iosefa, 1967; Tannenbaum, et al3 1974).
Carbenoxolone did not potentiate the activity of 
warfarin, which confirms the predictions from the study 
in vitro where different classes of binding site on human 
albumin were seen for the two drugs. Whereas warfarin was 
binding at only a.single class of site on human albumin, 
chlorpropamide was bound at two classes of site so that 
displacement from binding by either phenylbutazone or 
carbenoxolone was not certain, but possible. It was clear 
that phenylbutazone potentiated the pharmacological effect 
of chlorpropamide, whilst carbenoxolone did not. This 
finding leads to the suggestion that carbenoxolone binding 
did not prevent that of chlorpropamide, whilst phenylbutazone 
did prevent chlorpropamide binding to plasma proteins in the 
rat.
The initial results with tolbutamide and carbenoxolone 
were not as well defined. It appears-that, although there 
was no potentiation of tolbutamide activity, there was 
either an inhibition of activity or an elevation of blood 
glucose concentrations. Carbenoxolone is known to possess 
mineralocorticoid-like activity (Finney & T&rnoky, 1960). 
Further evidence for the lack of glucocorticoid activity was 
gained from preliminary studies in alloxan diabetic rats., 
where a similar rise in blood glucose concentration was obtained
with combined carbenoxolone and tolbutamide treatment; because it 
is known that glucocorticoids will cause an increase in 
gluconeogen6sis in the presence of normal insulin levels 
(Bell, et al3 1956). This finding also eliminates the 
possibility of interference with the absorption of the 
glucose load. It is interesting to note that carbenoxolone 
had no inherent activity on blood glucose levels when 
administered alone^ whereas glycyrrhetinic acid was observed 
to exhibit glycolytic activity in mice (Finney & Somers, 1958). 
However, from the studies with adrenalectomised rats, and the 
second treatment regimen in whole rats, it is clear that no 
alteration of the pharmacological activity of tolbutamide 
was induced by the presence of carbenoxolone and that the 
effect of-elevation of glucose levels by combined drug therapy 
was probably due to adrenal stimulation.
Neither phenylbutazone nor carbenoxolone induced any 
change in the pharmacological activity of phenytoin, in 
contrast to the effect upon chlorpropamide, which had 
exhibited a similar binding to phenytoin in the study in vitro. 
It is possible that phenytoin remained bound at an alternative* 
site to the two interacting drugs,or even became bound.to 
other proteins such as globulin. It must also be appreciated 
that phenytoin is not as highly bound to plasma proteins in 
the rat as it is in man and thus the pharmacological activity 
may not be significantly influenced by a slight change in the 
free drug concentration.
Thus with these findings from experimentation in vivo 
some of the predictions from the study in vitro are validated. 
Drugs binding at a single class of site on human serum albumin 
followed predictions and did or did not interact, depending on the classes 
of binding site involved. Of the drugs binding at two classes 
of site, chlorpropamide did interact.'with phenylbutazone, 
but not with carbenoxolone, whilst phenytoin did not interact 
.with either of these drugs. It is evident that influences 
other than plasma binding may be 'involved and that the plasma 
pharmacokinetics of these drugs should also be studied. Such 
studies'are presented in Chapter 5. '
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INTERACTIONS OF CARBENOXOLONE INVOLVING DRUG KINETICS IN VIVO
5.1 INTRODUCTION
Displacement of a drug from plasma binding sites, 
with the consequent modification of its pharmacological 
activity, is one aspect of interaction which was investigated 
in the previous chapter. An alternative aspect of 
displacement may result in an increased metabolism of 
the drug, due to a higher concentration of the free drug 
being made available for biotransformation. In addition 
to displacement an interacting xenobiotic may alter the 
rate of metabolism of the drug by enhancing or inhibiting 
enzymic activity.
The displacement of warfarin by phenylbutazone results 
in a reduced plasma half-life of warfarin (O’Reilly & Levy, 
1970) whilst the pharmacological activity of warfarin is 
enhanced, as demonstrated by Aggeler and colleagues (1967) 
and confirmed in the present study (Chapter 4).
In contrast, barbiturates increase the metabolism of 
warfarin in rat and man, but reduce its pharmacological 
activity in man whilst the drug distribution remains 
unchanged (Ikeda, et alj 1968; Levy, etal3 1970). Warfarin 
is a good example of the effect of plasma binding of drugs 
on their excretion, because it is non-polar and highly 
bound to plasma proteins thus resulting in high plasma 
levels. The hydroxylated metabolites of warfarin are more 
polar and only weakly bound to plasma proteins, therefore 
they occur in the urine in high concentrations (O’Reilly,
1969).
The pharmacological activity of tolbutamide is also 
potentiated by concomitant administration of phenylbutazone, 
but in this case the half-life of tolbutamide in blood is 
increased (Slade & Iosefa, 1967; Tannenbaum, et dl3 1974).
In the present study (Chaptei» 4) concomitant 
administration of carbenoxolone with either warfarin or 
tolbutamide did not alter their pharmacological activities. 
In the present chapter it is intended, therefore, to measure 
possible alternative effects of carbenoxolone on the blood 
half-lives of warfarin and tolbutamide. In addition, the 
effect of phenylbutazone on the half-lives of warfarin and 
tolbutamide will be monitored, to validate the experimental 
models.
A suitable model to assess the pharmacological 
activity of carbenoxolone in vivo does not, unfortunately, 
exist. Therefore, in order to evaluate possible displace­
ment of carbenoxolone by other drugs, serum levels of 
carbenoxolone will be measured in the presence of warfarin, 
tolbutamide, chlorpropamide and phenytoin. These measure­
ments will be carried out in rat and in man.
5.2 EXPERIMENTAL
5.2.1 CARBENOXOLONE-WARFARIN INTERACTION
Warfarin concentration in plasma was measured by the 
fluorescence method of Corn and Berberich (1967). The 
drug was extracted from 0.2 ml plasma into 4 ml acetone 
and the fluorescence measured at 340 nm (activation) and 
410 nm (fluorescence), using a Baird Atomic FP100 Fluoripoint 
spectrofluorimeter. The quenching of fluorescence by the 
addition of 0.05 ml 0.1 M HC1. was proportiona.l to the 
concentration of warfarin in the samples.
Groups of 8 female Biorex Wistar rats (200 + lOg) 
were fasted for 16 hours (overnight) prior to treatment 
and fed 8 hours later. Warfarin was administered orally 
as an aqueous solution at a dose level of lOmg/kg (5ml/kg). 
Carbenoxolone or phenylbutazone was administered 
at the same time as the warfarin, subcutaneously in 
0.9% NaCl (5ml/kg) at a dose level of twice the molar 
equivalent of warfarin, i.e. 40 and 20 mg/kg respectively. 
Blood samples were taken under ether anaesthesia from the., 
ventral aorta using >citrate/hepes buffer (0.13' M .trisodium 
citrate, 0.05 M .N-2-hydroxyethylpiperazine-N1-2-ethanesulphoni 
acid) as anticoagulant at a level of 0.1 ml per ml of 
blood collected. Plasma samples were prepared from blood 
collected at 1, 2, 4, 6, 8 and 24 hours after dosing.
5. 2. 2 CARBEN0X0L0NE-T0LBUTAMIDE INTERACTION '
Tolbutamide concentrations in whole blood were measured . 
by the spectrophotometric method of Kern ( 1 9 6 3 ) .  The drug 
was extracted from 1 ml whole blood into 8 ml 1,2-dichloroethane 
in the presence of 1 M citrate buffer at pH 4.6. After 
back extraction with 1 M ammonia solution the tolbutamide 
w a s .nitrated with potassium nitrate in sulphuric acid and 
then reduced with I chloride. The resultant product
.was diazotised and coupled with N(l-naphthyl)ethylene diamine 
and the absorption at 547 nm measured on a Pye Unicam 
SP500 spectrophotometer. ’ '
Groups of 8 female Biorex V/istar rats (200 + lOg) 
were fasted for 16 hours (overnight) prior to treatment.
All drugs were administered orally in 0.01% aqueous 
Tween 80 (5 ml/kg), tolbutamide at a dose level
of 50mg/kg, carbenoxolone and phenylbutazone at a dose 
level of twice the molar equivalent of tolbutamide, i.e.
227 and 114 mg/kg. Blood samples were taken under ether . 
anaesthesia from the ventral aorta, using heparin as anti­
coagulant. Tolbutamide concentration was measured from 
1 ml whole blood samples taken 1, 2, 4, 6 and 8 hours 
after treatment.
5. 2. 3 THE EFFECT OF VARIOUS DRUGS ON SERUM CARBENOXOLONE CONCENTRATION 
IN TEE RAT AND IN M N  .
Carbenoxolone serum concentration was measured by the 
gas chromatographic method of Rhodes and Wright (1974).
The drug was extracted from acidified serum with ether, 
the ether evaporated and the residue redissolved in ethanol, 
followed by 0.5 M Na^CO^. The alkaline solution was washed 
with ethyl acetate, the aqueous layer was then acidified 
and extracted with ether. The ethereal extract was then 
methylated by the action of diazomethane prior to injection 
on to a 1 foot 1% OV-1 glc column at 285°C.The internal standard 
used was 18-a carbenoxolone.
Rat study. Groups of 6 female Biorex Wistar rats 
(200 + lOg) were used for each estimation and fasted for 
16 hours (overnight) prior to treatment. Carbenoxolone 
(50mg/kg) and warfarin (lOmg/kg) were administered orally 
as aqueous solutions whilst phenytoin (40mg/kg), tolbutamide 
(50mg/kg) and chlorpropamide (50mg/kg) were administered 
in 0.01% aqueous Tween 80. Blood samples were taken under 
ether anaesthesia at 1,1,2, 4 and 8 hours after treatment.
Human study. Volunteers received a single oral dose of 
lOOmg carbenoxolone (2 Biogastrone* tablets) after which 
blood samples were taken at 1, 2, 4 and 8 hour intervals.
Blood samples were also taken prior to the administration of 
carbenoxolone. On a subsequent day each repeated
the carbenoxolone dose and took a concomitant dose of 
either warfarin (lOmg), tolbutamide (500mg), chlorpropamide 
(250mg) or phenytoin (lOOmg) after which blood samples 
were taken as before.
5.3 RESULTS
5.3.1 CARBENOXOLONE-WARFARIN INTERACTION
The results of the plasma assay of warfarin produced 
a linear fluorescence quenching over the range of warfarin 
concentrations employed (Fig. 5.1) with a correlation 
coefficient of 0.999.
Plasma concentrations of warfarin in the rat 
decreased in a uniform manner over an 8 hour period after 
dosing, and were just detectable 24 hours after treatment, 
by the -method of assay used. The plasma half-life of the 
drug was determined from regression analysis of log. 
plasma, concentration versus time and was 8,4 and 8.5 hours 
in the two control groups (Fig. 5.2).
Concomitant administration of phenylbutazone markedly 
reduced the plasma half-life of warfarin to 2.3 hours, 
resulting in a significantly lower plasma concentration at each
stage from 2 hours after treatment (Table 5.1). It is 
interesting to note that the warfarin concentration 8 hours 
after concomitant phenylbutazone treatment were just 
measurable and that no detectable warfarin was present 24 
hours after concomitant treatment. This effect of phenyl­
butazone is known and validates the model (O’Reilly & Levy,
1970).
In contrast, the concomitant administration of 
carbenoxolone did- not produce plasma warfarin concentrations which 
were significantly different from controls at any stage 
(Table 5.2).
The inference from these results using the rat is that 
the potentiation of the pharmacological activity of warfarin 
by phenylbutazone (section 4.3.1) and the increased rate of
o 0.5 i.o 1.5 2.0 2.5
Warfarin concentration
(/ig/ml)
Fig 5.1 THE VARIATION OF FLUORESCENCE QUENCHING WITH WARFARIN
CONCENTRATION
The method was based on the assay of C o m  and Berberich (1967). 
Warfarin was extracted from plasma into acetone and the fluorescence 
intensity measured at 3^0/^10 nm. Acidification of the plasma reduced 
the fluorescence in direct proportion to the concentration of warfarine
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Fig 5»2 PLASMA WARFARIN CONCENTRATION FOLLOWING ORAL TREATMENT OF '
- FEHAIE RATS WITH WABFAHIN
The points represent the means of 6 rats per group and are from 
2 experiments.
The rats were fasted for 16 hours and treated orally with an 
aqueous solution of warfarin at a dose level of 10 mg/kg. The rats 
were fed 8 hours after treatment.
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excretion of warfarin are due to displacement of warfarin 
from plasma binding sites by phenylbutazone. These results 
are in agreement with those of O ’Reilly and Levy (1970) 
in m a n .
5. 3.2 CARBEN0X0L0NE-T0LBUTAMIDE INTERACTION
The spectrophotometric absorption from the assay of 
tolbutamide in whole blood was linear over the range of 
concentrations observed in the rat (Fig. 5.3).
There was an exponential fall, of tolbutamide blood 
concentration over an 8-hour period following an oral dose of 
tolbutamide (Fig. 5.4). From regression analysis of log. blood 
concentration versus time (Table 5.3), the half-life'in blood was 
found to be about 3 hours. Concomitant administration of phenyl­
butazone increased the half-life to 6 hours, resulting in 
blood concentrations which were significantly higher than controls 
at each measurement from 2 hours after administration.
In contrast, concomitant treatment with carbenoxolone did 
not produce blood concentrations which were significantly different 
from controls at any stage (Table 5.4).
From the present results it may be inferred that the 
potentiation of the pharmacological activity of tolbutamide 
by phenylbutazone (section 4.3.2) may be partially due to 
the decrease in the rate of excretion of tolbutamide. 
However, it is clear that carbenoxolone does not alter the 
half-life of tolbutamide in blood in the rat.
5.3.3, THE EFFECT OF VARIOUS DRUGS ON SERUM.CARBENOXOLONE CONCENTRATION 
IN THE RAT AND IN MAN
None of the drugs administered with carbenoxolone 
caused any interference with the assay of carbenoxolone 
itself.
Rat study. In the fasted rat,' carbenoxolone was rapidly 
absorbed following an oral dose, a second peak
1.4 I*
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Fig 5.3 STANDARD CURVE FOR THE DETERMINATION OF TOLBUTAMIDE
The absorption of the tolbutamide- N(i-naphthyl) ethylenediamine 
complex was measured at 5^7 nm , from the assay of Kern (1963)* 
The points represent the means of duplicate estimations from vihole 
rat blood, using heparin as anticoagulant.
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•of carbenoxolone serum concentration was seen 2 hours after treatment, 
which was subsequently reduced with a half-life of 9.5 hours (Fig. 5.5). 
The two peaks of carbenoxolone serum concentrations may represent 
gastric and intestinal absorptions.. Hie serum concentrations measured by 
this selective method are of carbenoxolone per se and not 
a metabolite, enoxolone, in contrast to earlier studies 
using radiochemically-labelled materials (Parke,et at*
1963:&' 1972; Iveson, et al3 1971).
None of the drugs a.dministered concomitantly with 
carbenoxolone caused any significant changes in the pattern 
of serum concentrations in the rat (Table 5.5).
Human study. The rate of absorption of carbenoxolone 
was not as rapid in man as in the rat, although the 
volunteers were not fasted as were the rats (Table 5.6).
The serum half-life of carbenoxolone in the volunteers 
varied between 5.6 and 10 hours. Unfortunately, not all 
the volunteers adhered to the protocol, in that blood 
samples were taken at 6 hours after treatment (instead of 
1 hour) in two cases, and 5 hours after treatment (instead 
of 4 hours) in one case. The average serum half-life of 
carbenoxolone as Biogastrone has been previously found to 
be 13 hours (Baron, et al, 1975).
Phenytoin (Mr. W.). The concomitant dose of phenytoin 
caused a minimal change in the serum half-life of carben­
oxolone from 7.5 to 8.0 hours. This cannot be considered 
a significant difference.
Warfarin (Dr. B.). The volunteer who took warfarin with 
R
Biogastrone had a higher carbenoxolone serum concentration (up to 
26 jjg/ml) than the other volunteers • with a short serum 
half-life of 5.6 hours. The concomitant administration of 
warfarin produced no change in the serum half-life of 
carbenoxolone.
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Fig 5.5 SERUM CARBENOXOLONE CONCENTRATION FOLLOWING ORAL TREATMENT
' •~rr • s»t^«>4g«Lju n M******  ui  ■i||im o»i»iiini»,mt.Kiwi»mi aww—ipmi«wiii.i'i<MimiiiiiiMji>Hi i— ir  mu ■■mi mm w n
OF FEMALE). RATS WITH CARBENOXOLONE •
Each point represents the mean of 6 different rats per group. The 
rats were fasted for l6 hours prior to treatment, then dosed orally 
with carbenoxolone at a dose level of 50 mg/kg in aqueous solution. 
Serum concentrations were estimated by the method of Rhodes and Wright 
(1974) .
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Chlorpropamide (Dr, P.). The volunteer who took 
RBiogastrone and chlorpropamide had the lowest overall serum 
concentration of carbenoxolone but this decayed with the 
longest half-life, namely 10 hours.
The concomitant dose' of chlorpropamide inhibited the 
serum concentration of carbenoxolone from rising above 4 jig/ml 
until 6 hours after the dose when the serum concentration continued 
to rise, until the final measurement 8 hours after treatment. 
It was not possible to estimate a plasma half-life in this 
case.
RTolbutamide (Mr. 1.). The volunteer who took Biogastrone 
and tolbutamide displayed a very slow absorption pattern 
for carbenoxolone when taken alone, pea,k serum concentration was 
not achieved until 4 hours after ingestion of the dose.
When the second Biogastrone dose was taken with tolbutamide, 
peak serum concentration was achieved more, rapidly, i* e. by 2 hours, 
after which the serum concentration declined similarly, givin 
a half-life of approximately 6 hours.
5.4 CONCLUSIONS
The potentiation of the pharmacological effects of 
warfarin by phenylbutazone is well known and was 
demonstrated, in the rat (Chapter 4). The mechanism 
of potentiation is known to be mediated via the 
displacement of warfarin from plasma binding sites, 
resulting in a simultaneous reduction in the plasma half- 
life of warfarin (Aggeler, et al3 1967; O'Reilly & Aggeler, 
1968a). In the present studies the plasma, concentration of warfarin 
was greatly reduced in the presence of phenylbutazone, 
validating the model and confirming earlier predictions 
from studies in vitro (Chapter 3). Carbenoxolone showed no 
influence on warfarin plasma concentration. This finding 
is in accord with the previous demonstration of the failure 
of carbenoxolone to modify the pharmacological activity 
of warfarin and with the predictions from studies in vitro> 
that displacement interaction would not occur.
The pharmacological activity of tolbutamide was also potentiated 
by phenylbutazone, in the rat, but not by carbenoxolone. The former 
interaction is known in man (Tannenbaum, et al, 1974) and is 
mediated via an increase in the serum half-life of 
tolbutamide (Slade & Iosefa, 1967) which is confirmed in the 
present model in the rat. Although it is known that phenyl­
butazone will displace tolbutamide from plasma binding 
sites, it is probable that the main mode of potentiation 
is exerted via the inhibition of the metabolism of 
tolbutamide because of the ability of phenylbutazone, in 
an acute dose, to.inhibit the microsomal oxygenation system 
(Cho, et al3 1970; Griffin & D'Arcy, 1975).
The fact that carbenoxolone binds to., human serum 
albumin in vitro at differing sites to warfarin 
and tolbutamide led to the suggestion that carbenoxolone 
would not enter into displacement interactions with the 
two other drugs and this has been confirmed here. In 
addition, the serum half-life of carbenoxolone was
unaffected by concomitant administration of warfarin or 
tolbutamide both in rat and man, indicating that a reverse 
interaction has not occurred .
In contrast, carbenoxolone shared one of the two 
binding sites on human serum albumin for both phenytoin 
and chlorpropamide, therefore the possibility of inter­
action with these drugs involving displacement from 
binding sites exists. However, phenytoin caused no 
alteration of serum levels of carbenoxolone either in man 
or rat.
Conversely, chlorpropamide showed no effect upon the 
serum levels of carbenoxolone in the rat but appeared to 
reduce the absorption of carbenoxolone in man. However, 
the human results are based upon paired administrations in 
only one patient per interacting drug. The absorption of 
carbenoxolone in the presence of chlorpropamide was 
similar to that seen for carbenoxolone alone in the fourth 
volunteer (Mr. Y.) and may, in fact, be more closely 
linked with the times and contents of meals rather than 
the presence of a second drug. Carbenoxolone, as 
Biogastrone, is known to be absorbed more slowly' when taken 
after meals (Baron, et als 1975) and serum levels are lower 
in fed rats than in fasted rats used in the present , 
experiments (Gilbert, personal communication). It is 
interesting to note that tolbutamide did not cause a 
similar inhibition of carbenoxolone absorption, suggesting 
that the delay of.absorption is not likely to be due to an 
increased rate of insulin secretion.
The inferences from these results must be that 
carbenoxolone does not interact with warfarin, phenytoin, 
chlorpropamide or tolbutamide in the rat, nor do these 
drugs alter the serum half-life of carbenoxolone in rat or 
man. However, it is possible that chlorpropamide prevented 
the absorption of carbenoxolone in man.
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Chapter 6
FINAL DISCUSSION
This chapter presents an overall view of the 
experimental work completed, the conclusion*, s drawn and 
consequent suggestions for further research.
6.1 INTRODUCTION
Interaction of a drug with a xenobiotic, or a 
second drug, is a problem when changes in the bioavailability 
of the drug lead to an increased activity or toxicity.
These possible influences are summarised in Fig. 6.1.
For. a drug such as carbenoxolone, which is highly 
bound to plasma proteins, the available form may not 
necessarily be the 'active* form, because no correlation 
between blood levels and efficacy has been established.
Thus high blood levels of carbenoxolone are q. hazard and 
large free concentrations may be toxic, since the free drug 
has been shown to be a potent uncoupling agent of oxidative 
phosphorylation (Whitehouse, et al> 1967). The possible 
effects of other drugs on carbenoxolone, as a model of 
potentiation drug interaction, are summarised in Fig. 6.2.
In order to investigate possible interactions of this drug, 
its binding to plasma proteins was first investigated.
Experiments to evaluate protein binding-drug inter­
actions per se are generally performed in vitro and often 
with isolated protein fractions, such as bovine serum 
albumin. In the present study it was decided to carry 
out a correlation between such methods of study in vitro 
and to compare human and bovine serum albumins, with a 
view to extrapolation from studies in vitro with bovine 
albumin to the human clinical situation.
Before studying interactions in vivo it was considered 
necessary to carry out some form.of preselection of drug 
candidates, and this was based on the results of a single
>1
-p•H
>•H
-PO
bO
<U
£
Hnd
W
a
pqftco
CO
o
ft
ft0
1 
gOCO
i—I
VO
bl 
•rH
ft
ft
«Ho
d
o•H
-p
•H
-P
d
<D
-P
op-l
•a
do•H
-P
•rH
ft
•H
•S
•H
d
•H
bo
d
•H
ft
d
»
<D
d
03
-PO<u
«HtH(1)
03
-P
do
03
<X>
M
ft
<D
H
Jz;
O1—I
ft«£ftft
r 1% ftftP4 o
ft ft
H
O
H C§
O H
S
O
MH
<
P2
p H<2 S3
22 PDQ C 3 o<2 s pi—! o
Ps P3 o
£2O
M
fH
<
«
< S3
s P PCQ O
< a S3
P o O
P-. PQ O
53 @M U
W e H OQP CQ M a
P M  'Ph w< Pi M ofH -=i2 O <3U) Jit5 fp
5 P 03a <C Ph cq
'dWPH
C
CO
rOd
-P
o
s
CD
sdPMc
Pi
&o
i— !„CO
0 d dOd •Ho o •P-p •Ho ►X adrH •HjgO rH 2d d •HO o
>5
-P•HO•H
Xo
-p
C/3
rH
>
CD
rH
T3OC
r-irO
002
d0
Piod
•iH
02
-Prj
0
020ua0)PI
—
► 
Re
pr
es
en
ts
 
de
cr
ea
se
d 
bl
oo
d 
le
ve
ls
/t
ox
ic
it
y
study in vitro. The drugs used in the experiments in vivo 
were all subject to ’known' interactions with phenyl­
butazone, therefore this drug was used to validate the 
animal models prior to the investigation of the effects 
of carbenoxolone. Measurements of the pharmacological 
activities and blood concentrations of the drugs under 
study were made following administration of the drug 
alone and with carbenoxolone. Reciprocal measurements 
of the serum concentrations of carbenoxolone were made 
in the presence of these drugs in rat and man.
6.2 EXPERIMENTAL METHODS IN VITRO'
'Classical' methods of quantitative measurement of. 
protein binding use a visking dialysis membrane, but 
this membrane carbenoxolone to a significant degree.
The binding of macromolecules to visking membranes has 
not generally been acknowledged as a. problem by other 
workers. Carbenoxolone was bound to visking membranes perhaps 
because it is relatively larger (mol.wt. 615) than most 
other drugs, or because it is more lipophilic and hence 
more extensively bound to protein than other drugs.
However, this binding of carbenoxolone was reduced by 
various washing techniques and was found tc be a major 
problem only with dilute protein solutions. .
Comparison of the binding characteristics of carben­
oxolone in vitro did not result in a good correlation 
between the different methods. However, it is known 
that comparison of the results of binding studies, not 
only between different methods but also between laboratories, 
is not uniform (Swillens & Dumont, 1975; Vallner, et al3 
1976) and that minor variations in conditions such as 
pH or osmolarity may cause major differences in binding. 
Furthermore, the mathematical analyses employed may also 
introduce a known bias (Madsen & Robertson, 1974; Vallner,
• et al3 1976) .
A comparison of the results from different methods 
of measuring drug binding to both human and bovine serum 
albumins is presented in Table 6.1. From this survey 
it becomes clear that it is unwise to consider comparing 
the results of drug binding performed under differing 
conditions. Using a standard technique, namely equilibrium 
dialysis, under identical conditions, Chignell and 
Starkweather (1971b) have compared the binding of phenyl­
butazone to human, rat, dog and rabbit serum albumins.
The drug was bound most strongly to human albumin but significant 
differences in binding characteristics were observed for all four 
species studied. In the present study, even though the 
results obtained by differing techniques in vitro did not 
show good agreement, it was clear that human and bovine 
serum albumins presented differing binding characteristics 
for each drug studied.
However, in spite of the use of the same technique 
to measure drug binding, it is not clear whether the binding 
sites for different drugs on plasma proteins are, in fact, 
identical. Chignell and Starkweather (1971a) have 
demonstrated changes in drug binding to human serum 
albumin, following acetylation of the albumin b y  aspirin. 
The binding of phenylbutazone to acetylated albumin was 
increased, whereas that of flufenamic acid was decreased 
and that of dicoumarol was unchanged. . These findings lead to
the suggestion that apparently identical binding sites are, 
in fact, quite different. It is also appreciated that 
albumin itself may be sufficiently modified, by 
fractionation to the crystalline form, to ca.use a change 
in drug binding characteristics (Olsen, 1972; Kostenbauder, 
et ala 1970).
Therefore, if measurements of protein binding in vitro are 
to have'relevance to the human clinical situation, then 
•human.albumin should be used in preference to that of 
non-human species.
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Measurement of binding characteristics 
of a drug by the use of a fluorescent probe was confirmed 
as a suitable and relevant technique by comparison with 
other established methods for the known binding of 
phenylbutazone and warfarin.' The fluorescent probe 
was the method chosen to investigate the
comparative binding of carbenoxolone and several other 
drugs.
O f  f«£
6.3 COMPARA^O'K)^PROTEIN-BINDING OF CARBENOXOLONE WITH 77/*T O F  
OTHER DRUGS IN VITRO
From a study of the binding of some 14 different
drugs to human serum albumin, of a fluorescent
■ \ ■ ■ 
probe, it is evident that the drugs can be classified
into 3 groups. There are 2 distinct, drug binding sites
present in human albumin; 2 of the groups of drugs bind
at only one site and the third group binds at both sites.
The group bound only at the first class of 
site (n = 1) includes carbenoxolone, which was the most 
strongly bound member of its group. This finding suggests 
that carbenoxolone would displace the other members of its 
group, namely, cicloxolone, indomethacin, enoxolone and 
cholesterol f.rom albumin binding sites. In contrast, 
carbenoxolone. would not displace drugs of -the second 
group, flufenamic acid, phenylbutazone, warfarin, 
tolbutamide and imipramine, which are bound at the alternative 
binding site (n = 3). The other drugs which
carbenoxolone might displace were the third group, 
that . is prednisolone, aspirin, ibuprofen,
chlorpropamide and phenytoin, all of which bind at both 
sites and hence share the carbenoxolone binding site.
Evidence.for the validation of the fluorescent 
probe method was obtained by comparison of the orders 
of displacement of drugs with 'those obtained 
by established methods. These are: phenylbutazone^ 
warfarin> tolbutamide, and between groups;
indomethacin )> aspirin and warfarin > phenytoin (Stockley,
1971; O ’Reilly & Levy, 1970; Assandri & Perazzi, 1976).
It is also suggested that within each group those drugs 
with the highest binding affinities would displace the . , 
members with lower affinities.
The clinical consequences of carbenoxolone displacing 
the triterpenoids, cicloxolone and enoxolone, are minimal 
because these drugs are never likely to be administered 
concomitantly. However, the pharmacology and toxicity of 
cicloxolone are very similar to those of carbenoxolone, 
thus the toxic effects may be increased by an elevated 
concentration of free cicloxolone. Displacement of 
indomethacin, from plasma binding sites, by carbenoxolone 
may result in an enhanced central toxicity such as 
dizziness (Martindale, 1977). However, the gastro-intestinal 
irritation and ulcerogenisis of indomethacin may not be 
potentiated because of the protective effects of carben­
oxolone. Because both indomethacin and carbenoxolone are 
excreted in the bile, there may be competition for the 
mechanisms of biliary excretion. It is possible that the 
anti-inflammatory actions.of indomethacin may be increased 
by concomitant administration of carbenoxolone, not only 
from a possible increased concentration of free indomethacin, 
but from simple addition with the anti-inflammatory 
activity of carbenoxolone itself (Thornton, MacDonald,
Sacra & Gottfried, unpublished observations). However, 
it is interesting to note that such synergism is not 
observed between carbenoxolone and phenylbutazone, which 
bind at different sites on human serum albumin (Thornton 
& Sacra, unpublished observations). Displacement of 
cholesterol by carbenoxolone may result in an increase in 
the rate of cholesterol metabolism or an increase in the 
deposition of cholesterol in atherosclerotic plaques.
However, long-term toxicity studies in rats and dogs, and 
indeed a long clinical history, have produced no evidence 
to suggest that either of these interactions with 
cholesterol is of clinical significance.
Should carbenoxolone displace prednisolone, aspirin, 
ibuprofen, chlorpropamide or phenytoin from their common 
binding site on human albumin, then these drugs may remain 
bound at alternative sites and thus not result in an 
increased free concentration of displaced drug. However, 
indomethacin is known to displace aspirin from plasma 
binding sites in vitro, but when the displaced aspirin binds 
at its alternative site, a possible conformational change 
results in aspirin displacing indomethacin in vivo (Mason 
& McQueen, 1974). Therefore it is possible that this group 
of drugs may displace carbenoxolone from plasma binding 
sites in vivo.
However, the binding capacity of human albumin for 
carbenoxolone must be considered in relation to possible 
displacement interactions. The present studies with 
diluted human serum albumin have demonstrated that the 
binding capacity for carbenoxolone may be in excess of 
28 days accummulated dose at a regimen of 300 mg/day. 
Therefore there is a considerable reserve of plasma albumin, 
and other plasma proteins, which will bind therapeutic 
concentrations of carbenoxolone.
From the present results it is evident that the 
fluorescent probe technique is a rapid, sensitive method 
for measuring drug-albumin binding. The complications 
of radio-labelled drugs or of membrane binding are not 
encountered with this method. Therefore,it is ideally 
suited to the evaluation of the binding of new drugs to 
serum albumin prior to study in vivo.
’6.4 CARBENOXOLONE INTERACTIONS IN VIVO
It is not always possible to predict interactions 
m  vivo from studies in vitros due to such factors as drug 
metabolism and protein dilution (Olsen, 1972). Phenyl­
butazone displaces prednisolone from plasma binding sites 
but does not alter its plasma half-life, therefore the
elimination of prednisolone is not dejjendant upon its 
degree of protein binding (Maickel, et al3 . 1966).
Animal models of interaction in vivo are useful for 
comparison with studies in vitro but contain known 
hazards in the extrapolation of results to the human 
clinical situation, due to species differences (Brodie, 
196'2; Williams, 1974, 1978). Therefore, in the present 
studies of drug interactions in rat, ‘classical’ inter­
actions known to occur in man were included to evaluate 
the animal model.
Phenylbutazone is a drug which is highly bound to 
plasma proteins and known to potentiate the pharmacological 
actions of warfarin, tolbutamide and chlorpropamide (see 
as example Stockley, 1974). These interactions were 
readily demonstrated in the rat in vivo. Under the same 
experimental conditions carbenoxolone did not alter the 
pharmacological activity of these drugs providing 
confirmation of the results from studies in vitro.
Warfarin is a classical example of the effects of 
displacement interaction on its rate of metabolism. The 
plasma half-life of warfarin is decreased following 
displacement from plasma binding sites by phenylbutazone. 
This increased free concentration of warfarin
results in an enhanced anticoagulant action (O'Reilly & 
Levy, 1970). Phenylbutazone is also known to displace 
tolbutamide from plasma binding sites and to potentiate 
its glucose-lowering action. In this case the plasma 
half-life of tolbutamide is increased, probably due to 
inhibition of the metabolism of tolbutamide by phenyl­
butazone (Slade & losefa, 1967; Cho, et al3 1970). These 
changes in the plasma pharmacokinetics of warfarin and 
tolbutamide were also easily demonstrated in the fat in the present 
study. Furthermore, carbenoxolone did not interact to produce 
alterations in the plasma levels of these two drugs.
This confirms the predictions from the 'results
in vitro3 in that no displacement from plasma binding was 
observed. In addition, it is clear that carbenoxolone 
exerted no effect upon the elimination of tolbutamide 
from blood, following an acute dose.
Phenytoin and chlorpropamide differed from warfarin 
and tolbutamide in the results of the binding study in 
vitro. The former two drugs shared only one of their two 
binding sites with phenylbutazone. Potentiation of the 
glucose-lowering action of chlorpropamide was demonstrated 
in vivo by phenylbutazone but not by carbenoxolone, 
suggesting that carbenoxolone and chlorpropamide may be 
satisfactorily bound to plasma albumin at separate sites at the same 
time. In contrast, the pharmacological action of phenytoin 
in vivo was not affected by either concomitant treatment 
with phenylbutazone or with carbenoxolone. It is known 
that phenytoin is bound less strongly to plasma proteins 
in rat than in man and this may account for the Tack of 
significant interaction (Conard, et al3 1971). Therefore this finding 
leads to the suggestion that, for phenytoin, the rat is 
not a suitable model for interaction studies.
Carbenoxolone failed to alter the pharmacological 
effects of any of the drugs with which it was administered 
concomitantly. However, these experiments did not provide 
any information as to whether carbenoxolone itself may 
have been displaced from plasma.binding sites. Because of 
the difficulty in assessing the pharmacological activity 
of carbenoxolone, serum concentrations of carbenoxolone, in 
the presence of other drugs, were measured in rat and in 
m a n .
None of the drugs administered concomitantly with 
carbenoxolone, namely warfarin, tolbutamide, phenytoin and 
chlorpropamide, altered the serum concentrations of 
carbenoxolone in the rat. It was anticipated, from studies 
in vitro3 that neither warfarin nor tolbutamide would affect
serum concentrations of carbenoxolone but chlorpropamide 
and phenytoin both share a carmon binding site with carbenoxolone and 
thus may have displaced carbenoxolone from its binding 
site. However, an almost identical pattern of carben­
oxolone .concentrations were seen in man and rat, with the exception 
that chlorpropamide may have initially inhibited the 
absorption of carbenoxolone in man.
In conclusion, it may be inferred that carbenoxolone 
is free from many of the untoward interactions associated 
with other drugs which are highly bound to plasma proteins. 
However, only a small number of drugs were evaluated in 
vivo and caution must always be exercised when introduein 
a new drug combination in man.
6.5 PROPOSALS FOR FUTURE RESEARCH
Whatever the answers to a research question are, they 
always stimulate further questions.
For binding studies in vitro it would be of value to 
use fluorescent probes with differing structures to
those used in the present study. A basic fluorescent 
probe would be novel. In order to study the species 
differences of plasma-drug binding, purified albumin 
fractions from various species would be 
extremely valuable in the use of fluorescent probe 
techniques.
Whilst a fairly comprehensive group of drugs was 
screened in the fluorescent probe study, the addition of 
other classes such as the benzodiazepines, and new drugs 
such as diflunisal and cimetidine, would be of interest.
Carbenoxolone is excreted in the bile and'competition 
with other compounds for this route of excretion, whilst 
not directly related to plasma binding, may be of interest.
Phenytoin undergoes extensive biliary excretion and 
enterohepatic circulation in the rat and is therefore a 
suitable candidate■for this study (Noach, et al3 1958).
Evaluation of potential interactions of drug candidates
It is impossible to evaluate all new drugs or, for 
that matter, established drugs, for interactions with all 
other clinically used agents.
One of the early investigations which may be made is 
to evaluate whether a drug candidate is bound to plasma 
proteins. For this the fluorescent probe method is 
eminently suitable. If the drug is bound to plasma 
proteins then the relative binding between laboratory 
species and man should be assessed, preferably in vitro 
and by the fluorescent probe method, using albumin 
fractions. These results may assist in the choice of an 
appropriate laboratory species for toxicological tests.
Studies in vivo may follow two lines of approach, the 
effect upon 'classical' drugs, such as warfarin and 
tolbutamide, and the effect of enzyme-inducing agents, 
such as barbiturate and phenylbutazone, upon the plasma 
levels of the drug. It is preferable to use a laboratory 
species for toxicity studies where plasma binding and drug 
metabolism is similar to that in man. The effect of the 
new drug upon drug-metabolising enzyme systems is also 
important and may be assessed on such models as 
barbiturate-induced sleeping times and the plasma half-life 
of a suitable drug, such as warfarin.
Although much caution should accompany new drug 
combinations there is a danger of inducing, in the words 
of Azarnoff(1974), 'a drug-interaction-anxiety syndrome'.
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